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Preface
Neuroprotection is a key approach to maintaining brain health to prevent the 
retraction of synapses, accumulation of neurodegenerative proteins (tau, β-amyloid 
peptide, α-synuclein, huntingtin, or any misfolded proteins), activation of neuroin-
flammation, or even the breakdown of the blood-brain barrier. Neuroprotection can 
be applied to chronic neurodegenerative diseases (Alzheimer’s disease, Parkinson’s 
disease, Lewy’s body diseases, Huntington’s disease, amyotrophic lateral sclerosis, 
or even brain tumors), acute neurological disorders (brain trauma, stroke, transient 
ischemia, epilepsy, or cerebral hemorrhage), or even mental disorders (psychosis, 
depression, or schizophrenia). The traditional view of neuroprotection is often 
restricted to the use of agonists or antagonists of neurotransmitter receptors. While 
this is still a great approach to safeguard neurons, neuroprotection strategy is not 
limited to modulating neurotransmitter receptors. Neuroprotection can be accom-
plished by (1) natural products, (2) herbal medicine, (3) different forms of exer-
cise, (4) learning new skills or languages, or (5) even good sleeping patterns. From 
all these new perspectives, the concept of neuroprotection is limited not only to the 
protection of neurons in the pathogenesis of diseases but also to the prevention of 
any detrimental factors leading to neuronal cell loss.
The major aim of this book is to focus on different approaches to achieve neuropro-
tection. In this book, most of our authors review the advantages of neurotransmit-
ter receptors. Mititelu-Tartau and Bogdan’s group reviews the imidazoline ligands 
and opioid ligands in Alzheimer’s disease. They review the neuroprotective effects 
of agmatine on memory. In addition, they also summarize the findings of using 
different opioid receptor ligands to elicit neuroprotection. Similarly, Yanuar’s group 
reviews the beneficial effects of the adenosine A2A receptor antagonist. It has been 
reported that the adenosine receptor antagonist elicits neuroprotective effects, par-
tially because of its signaling pathways to activate the cytosolic fraction of cAMP. 
Yanuar’s group reviews how A2A antagonists provide neuroprotection. 
Apart from modulating neurotransmitter receptors, Flood’s group reviews another 
very important pathological factor leading to neurodegeneration: neuroinflamma-
tion. Microglial cells are the major line of cells to be activated to produce cytokines 
and free radicals to damage neurons. Interestingly, Flood’s group reviews how dif-
ferent adrenergic receptor agonists and antagonists modulate microglial responses. 
This independent review suggests that modulation of neuroinflammation can also 
be achieved by intervening neurotransmitter receptors and their associated signal-
ing events. 
Neuroprotection can be disease specific but use different approaches. Nian and 
Lo review the neuroprotection of aging eyes, in which aging-associated macular 
degeneration often occurs in the elderly. With the progression of the disease and 
identification of biological targets at different states of the disease, the strategy of 
neuroprotection can be changed.
Taken together, neuroprotection receives increasing attention from different 
approaches in different states of neurodegenerative diseases, acute neurological 
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disorders, and even mental disorders. Even in disease progression, neuroprotection 
can prevent the spread of neuronal damage or neuronal loss from one region to 
other regions. This book will give insights to scientists in the field to stimulate their 
research, medical professionals to review their clinical practices, and others who 
would like to learn more about different neuroprotective approaches.
Raymond Chuen-Chung Chang, PhD
Laboratory of Neurodegenerative Diseases,
School of Biomedical Sciences,
LKS Faculty of Medicine,
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Introductory Chapter: Concept 
of Neuroprotection - A New 
Perspective
Raymond Chuen-Chung Chang and Yuen-Shan Ho
1. Introduction
Neuroprotection is an approach to preserve neurons so that neurons cannot 
be hurt by different pathological factors in neurodegenerative diseases. It can be 
an approach before the onset of the disease so that neurons cannot be affected by 
any risk factors. It can also be an approach during the progression of the disease to 
prevent spreading of injury from one neuron to neighboring neurons. Therefore, 
neuroprotection can also be one approach as “disease-modifying agent” to delay and 
even stop progressive neurodegeneration.
The concept of neuroprotection has long been confined to intervene neurotrans-
mitter receptors via agonists and antagonists. A very well-known example is the 
neuroprotective effect of caffeine via adenosine receptor, because caffeine is an A2 
receptor antagonist. Caffeine can exert neuroprotection via adenosine A2 receptor 
to protect dopaminergic neurons in an experimental model of Parkinson’s disease 
(PD) by using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a toxin 
agent [1]. Therefore, drinking coffee has been considered to be neuroprotection. 
Apart from adenosine receptor on neurons, it is now known that microglial cells 
also express A2 receptor, and A2 receptor antagonist or caffeine can reduce activa-
tion of microglial cells [2]. Since caffeine or A2 receptor antagonists can protect 
neurons and minimize activation of microglial cells, research is still very active in 
this direction. Indeed, investigation of other neurotransmitter receptor antagonists, 
agonists, blockers, or even partial blockers is still a very active research area in 
neuroprotection.
While it is exciting to reveal differential neuroprotective effects via modulating 
receptors for different neurotransmitters, we should not restrict ourselves to this 
perspective only. In fact, a wider scope of neuroprotection has been evolved. The 
concept of neuroprotection can now be categorized into three groups: (A) pharma-
cological intervention, (B) non-pharmacological intervention, and (C) cellular and 
genetic approaches (Figure 1).
In group A neuroprotective approaches, pharmacological intervention includes 
modulation of neurotransmitter receptors (as introduced above), anti-oxidative 
stress, and anti-inflammatory responses [3]. These are classical pharmacologi-
cal approaches. These methods have been explored for decades and can be used 
for both neuroprotection and as disease-modifying agents. Their effects can be 
target-specific for one single protein (e.g., receptor for neurotransmitter or one 
type of cytokines) or pathway-specific (anti-oxidative responses using nuclear 
factor erythroid 2-related factor 2, Nrf2). Since single biological target may limit 
the beneficial effects and may not be able to intervene the complexity of the disease 
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progression, neuroprotective effects from herbal medicine or natural products 
receive increasing attention in scientific research because of their multiple effects 
on different biological targets [4–6]. For example, it has been shown that triterpe-
noids extracted from Prunella vulgaris has anti-inflammatory effects [7]. We have 
proved that polysaccharide part of Prunella vulgaris can modulate the immune 
responses of microglia and macrophages [8, 9]. Therefore, Prunella vulgaris exerts 
neuroprotection toward neurodegenerative diseases against neuroinflammation.
In group B neuroprotective approaches, non-pharmacological approaches 
receive increasing attention. Since it is quite difficult to ask a healthy adult or even 
elderly to constantly take medicine even though it is herbal, non-pharmacological 
approaches to earn neuroprotection are most welcome. Among these different 
methods, exercise is the best to prevent nearly all kinds of diseases. Exercise can be 
further divided into aerobic and resistance exercises, in which aerobic exercise is 
suitable for motor-healthy adults or elderly. However, there is a large population of 
elderly who have difficulty in their motor functions. Resistance exercise becomes an 
excellent tool for them. Both aerobic and resistance exercises can affect the metabo-
lisms of the body and induce trophic factors like myokines, released from muscles 
and liver [10, 11]. Since body metabolism is important, diet control is also impor-
tant to reduce any risk factors leading to the development of neurodegenerative 
diseases, such as diabetes, hyperlipidemia, or hypercholesterolemia. All of these 
risk factors are related to vascular components, which may further add on vascular 
dementia [12–14]. Apart from exercise, it is well-known that, maintaining social 
activity is essential to keep our brain healthy [15]. In addition, sleeping can promote 
clearing of pathological factors, such as β-amyloid (Aβ) peptide and phosphory-
lated tau protein [16, 17]. Also, it has been recently shown that learning second 
language or bilingualism can be neuroprotective [18]. Furthermore, increasing lines 
of evidence have shown that acupuncture can help adjusting the body metabolism 
and immunity [18, 19]. Therefore, acupuncture can also be considered to be one 
method in non-pharmacological approaches. One key point should be noticed that 
all these neuroprotective approaches are multiple targets. This may be why they are 
so effective in minimizing neurodegeneration to preserve neurons.
Neuroprotective approaches in group C are the new extension of multiple 
effects from trophic factors secreted by genetically engineered cells or viral vector. 
Alternatively, stimulating the proliferation and differentiation of endogenous stem 
Figure 1. 
A summary of different neuroprotective approaches.
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cells, application of induced pluripotent stem cells (iPSC), or mesenchymal stem 
cells are popular trends in scientific research to prevent neurodegeneration and 
neuronal loss [20–22].
Since there are several chapters about the effects of neurotransmitter receptors, 
we will focus on some neuroprotective approaches only, as this is an introductory 
chapter.
2. Neuroprotective effects of herbal medicine and natural products
This direction of neuroprotection is the most controversial approach among dif-
ferent pharmacological tools. This is because most of the herbal medicine or natural 
products have a wide array of effects. If we use traditional way of thinking to target 
a specific protein or signaling pathway, herbal medicine fails to do so. However, 
if we are aware of neurodegenerative diseases that are usually multifactorial, we 
can then accept that herbal medicine should be the direction to prevent neuronal 
loss and spreading of neurodegeneration. Our group has long been working on 
discovering herbal medicine as neuroprotective agents and investigating their 
underlying mechanisms. Since most of the herbal medicines are in decoction form, 
for oral consumption, the effective components in different herbs are not limited 
to one single chemical. The small molecules being extracted from one herb can also 
be found from other herbs. There are many laboratories investigating those small 
molecules and have Research and Development (R&D) to be commercial products. 
In contrast, big molecules such as polysaccharides have been an unexplored area. In 
fact, a large portion of components from herbs is polysaccharides. When we use hot 
water to prepare decoction, what we can easily absorb is polysaccharides. Therefore, 
we have investigated polysaccharides extracted from different herbs [23].
We have first found that polysaccharides from Nerium indicum exert neuroprotec-
tive effects against β-amyloid (Aβ) neurotoxicity cultured neurons [24, 25]. Then, we 
also found that neuroprotective effects of Verbena officinalis and Ganoderma lucidum 
[26, 27]. Having investigated different herbal medicine, we found that the polysac-
charides from Lycium barbarum (Wolfberry) are potent [28, 29]. Polysaccharides 
can be extracted in hot water or from alkaline condition and elicit neuroprotection 
[30]. It should be noted that not all polysaccharides, but only some sub-fractions 
provide neuroprotective effects. Apart from neurons in the brain, polysaccharides 
from wolfberry can also protect the retina against experimental glaucoma and stroke 
[31–33]. As harvesting and planting processes have good agricultural practice and the 
extraction can be done under stringent control of good manufacturing practice, we 
choose wolfberry as our long-term study. Wolfberry is indeed an anti-aging Chinese 
herbal medicine. We would like to understand the concept of “anti-aging.” Therefore, 
we have investigated its application in different aging-associated neurodegenerative 
diseases [34]. In fact, not all aging-associated neurodegenerative diseases can be 
attenuated by the polysaccharide fraction of Wolfberry. In Parkinson’s disease (PD), 
more potent antioxidants are required to provide neuroprotection.
In experimental PD using 6-hydroxydopamine (6-OHDA) as toxin agent, we 
employed oxyresveratrol, which is a natural product but a structural analog of 
resveratrol, and found that it can attenuate neurodegeneration [35, 36]. For this 
kind of neurodegenerative disease requiring high levels and high capacity of anti-
oxidant, another method is to employ pro-drug approach so that oxidant cleave the 
precursor and the product becomes potent antioxidant. Interestingly, polyphenol 
(-)-epigallocatechin-3-gallate (EGCG) from green tea falls in this category [37].
The advantages of using herbal medicine or natural products are to make use 
of their multiple effects. In neurodegenerative diseases, a wide array of stress 
responses is stimulated because of free radicals or accumulation of misfolded or 
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badly folded proteins. Most of the herbal medicine and natural products attenuate 
many stress kinases. They may not be a good candidate to clear accumulation of bad 
proteins; however, they can inhibit the cascades of stress responses (e.g., activa-
tion of c-Jun-N-terminal kinase, JNK; endoplasmic reticulum stress pathways), 
which usually lead to neuronal apoptosis. Some of the herbal medicine or natural 
products can even strengthen the survival signaling pathways such as mTOR or Akt 
pathways.
In addition to their direct effects on neurons, there are many herbal medicine or 
natural products that can modulate body immune responses. For example, polysac-
charides fraction from Prunella vulgaris L. can modulate innate immune responses 
of macrophages [8, 9]. It has been increasingly aware that activation of body 
(systemic) immune responses are the origin of our sickness responses leading to low 
appetites and even fever [38]. Long-term effects of systemic immune responses can 
even result in psychological depression or acute delirium [39]. Experimentally, we 
have shown that infection in the body or immune responses triggered by surgery 
(laparotomy) can modulate cognitive functions because of stimulation of neu-
roimmune responses [40, 41]. Therefore, modulation of body immunity can be a 
powerful method to minimize neuroimmune responses and then reduce cognitive 
dysfunctions.
3. Aerobic and resistance exercises
As emphasized above, the advantages of herbal medicine and natural products 
are their multiples and wide array effects. Similarly, exercise is another method to 
achieve this goal. Exercise can stimulate production of different trophic/growth fac-
tors, e.g., vascular endothelial growth factor (VEGF), brain-derived neurotrophic 
factor (BDNF), insulin-like growth factor-1 (IGF-1), peroxisome proliferator-
activated receptor gamma coactivator-1α (PGC-1α)/neuronal fibronectin type 
III domain-containing protein 5 (FNDC5). Some trophic factors can be secreted 
by muscles or liver, which is collectively called myokines. It has been shown that 
muscle cells can produce PGC-1α, irisin, cathepsin B, myostatin (growth differen-
tiation factor 8), fibroblast growth factor 21 (FGF-21), IL-6, IL-15, myonectin, and 
SPARC (osteonectin) as novel brain-beneficial myokines [10, 42]. Some of them, 
such as FGF21, can also be secreted by the liver or even in the brain upon exercise 
[43]. They all can affect muscle, liver, adipose tissues, and brain cells, leading to 
preservation of cognitive functions, modulating the lipid metabolism, and immune 
responses [44]. This kind of myokine can pass through the blood-brain barrier.
For motor-healthy subject, aerobic exercise is beneficial to majority of people. 
As discussed above, myokines can be induced so that they provide neuroprotective 
effects to the brain and attenuate any systemic immune responses. While aerobic 
exercise is known to be good, a great number of elderly and demented patients 
could not enjoy the benefit of aerobic exercise. Those patients may have prior knee 
replacement or fall down hurting the legs. They may be lying down on the bed. No 
matter how we advocate the beneficial effects of aerobic exercise, this will not be 
beneficial to this group of patients. Does it mean that they will not have any benefi-
cial effects of exercise? This question leads us to investigate the beneficial effects of 
resistance exercise.
In a systematic review, aerobic exercise shows beneficial effects on cognitive 
functions and executive functions, which is better than that from resistance exer-
cise [45]. Furthermore, aerobic exercise seems to elicit strong anti-inflammatory 
effect than that of resistance exercise [46]. However, resistance exercise seems to 
particularly increase the volume of hippocampus [47]. A study in laboratory animal 
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has shown that aerobic exercise can markedly increase BDNF; whereas, resistance 
exercise can significantly increase IGF-1 [48]. Although resistance exercise may 
have some limitations, this is still a good choice for those elderly and dementia 
patients to have this form of exercise. IGF-1 can still elicit multiple functions in the 
brain to preserve neurons.
4. Concluding remarks
Since this is an introductory chapter, we do not intend to discuss every single 
method of neuroprotection in detail. We should keep in mind that neurodegenera-
tive diseases are multiple-hit processes. Therefore, no single biological target can 
afford all neuroprotective needs. Approaches in using herbal medicine and natural 
products remind us that multiple biological targets may be the way to exert effec-
tive neuroprotection. Therefore, any non-pharmacological approaches including 
exercise and even the new stem cell approaches exert multiple effects. This can be 
the way for our effective neuroprotective strategies.
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Abstract
Due to brain plasticity, the nervous system is capable of manifesting behavioral
variations, adapted to the influences from both external and internal environment.
Multiple neurotransmitters are involved in the mediation of pathological processes
at the molecular, cellular, regional, and interregional levels participating in cerebral
plasticity, their intervention being responsible for various structural, functional,
and behavioral disturbances. The current therapeutic strategies in neuroprotection
aim at blocking on different levels, the molecular cascades of the pathophysiological
mechanisms responsible for neuronal dysfunctions and ultimately for neuronal
death. Different agents influencing these neurotransmitters have demonstrated
beneficial effects in neurogenesis and neuroprotection, proved in experimental
animal models of focal and global ischemic injuries. Serotonin, dopamine, gluta-
mate, N-methyl-D-aspartate, and nitric oxide have been shown to play a significant
role in modulating nervous system injuries. The imidazoline system is one of the
important systems involved in human brain functioning. Experimental investiga-
tions have revealed the cytoprotective effects of imidazoline I2 receptor ligands
against neuronal injury induced by hypoxia in experimental animals. The
neuroprotective effects were also highlighted for kappa and delta receptors, whose
agonists demonstrated the ability to reduce architectural lesions and to recover
neuronal functions of animals with experimentally induced brain ischemia.
Keywords: neuroprotection, neurodegenerative diseases, ischemic stroke,
imidazoline, opioids, nitric oxide
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Increase in life expectancy has led to aging of the population and consequently
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1. Introduction
Increase in life expectancy has led to aging of the population and consequently
to an expansion of the prevalence of neurodegenerative diseases (NDDs) [1].
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Neurodegeneration represents a loss of neurons and their structural components
(dendrites, axons, and synapses) with a corresponding gradual atrophy in neuronal
function [2].
Clinical type Disease/disorder
Signs of progressive dementia




• Some cases of Lewy-body disease
• Posterior cortical atrophy (visuospatial dementia)
Signs of progressive dementia
accompanied by other
neurological abnormalities
• Huntington’s disease (chorea)
• Lewy-body disease (Parkinsonian features)
• Some cases of Parkinson’s disease
• Corticobasal ganglionic degeneration
• Cortical-striatal-spinal degeneration (Jakob’s disease)
• Dementia-Parkinson-amyotrophic lateral sclerosis complex
• Cerebrocerebellar degeneration
• Familial dementia with spastic paraparesis, amyotrophy, or
myoclonus
• Polyglucosan body disease
• Frontotemporal dementia with parkinsonism or ALS
Signs of movement disorders or
other posture abnormalities • Parkinson’s disease
• Multiple system atrophy
• Essential tremor
• Progressive supranuclear palsy
• Dystonia musculorum deformans
• Huntington’s disease (chorea)
• Acanthocytosis with chorea
• Corticobasal ganglionic degeneration
• Lewy-body disease
• Restricted dystonia
Signs of progressive ataxia
• Spinocerebellar ataxias
• Cerebellar cortical ataxias
• Complicated hereditary and sporadic cerebellar ataxias
Signs of slowly developing
muscular weakness and atrophy • Motor disorders with amyotrophy
• Spastic paraplegia without amyotrophy
Sensory and sensorimotor
disorders • Hereditary sensorimotor neuropathies
• Pure or predominantly sensory or motor neuropathic
• Riley-Day autonomic degeneration
Signs of progressive blindness
with or without other
neurological disorders
• Pigmentary degeneration of retina
• Stargardt’s disease




• Pure neurosensory deafness
• Hereditary hearing loss with retinal diseases
• Hereditary hearing loss with system atrophies of the nervous
system
*Adapted from Ropper A, Samuels M, Klein J. Adams and Victor’s Principles of Neurology. 10th ed. McGraw-Hill
Education; 2014.
Table 1.
Neurodegenerative diseases: main clinical types.
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Neuroprotection
NDDs (e.g., Alzheimer’s disease, Parkinson’s disease, Huntington’s disease,
dementia with Lewy bodies) determine cognitive and memory deterioration or
alteration of the ability to move, speak, and breathe. These chronic and progressive
disorders are an important cause of reduced quality of life, morbidity, caregiver
burden and also, of the increase in total healthcare expenditure [3–5]. Table 1 lists
the main clinical types of NDDs [6].
Neuroprotection can be defined as a “relative preservation of neuronal structure
and/or function” or as an action that aims “to prevent neuronal damage over time
(either acute or chronic)” [7]. Neuroprotective action is primary if it is exerted
directly on the neuron, or secondary if it appears from an activity on an intermedi-
ary that endangers neuronal function [8].
The mechanisms by which most agents with efficiency in NDDs act are not fully
elucidated, requiring multiple and in-depth experimental and clinical studies.
Several experimental investigations highlight the multiple and various inter-
relations between adrenergic, serotoninergic, dopaminergic, glutamatergic, opi-
oid, imidazoline systems, and the nitric oxide pathways, which may elucidate
the effects of different compounds involved in the mediation of pathogenic
mechanisms responsible for numerous structural, functional, and behavioral
disturbances.
This chapter presents a brief overview of the most studied mechanisms related
to neuroprotection and details the possibilities to pharmacologically influence
through the main known neurotransmitters the pathophysiological mechanisms
linked to various NDDs.
2. The imidazoline system
Imidazoline receptors are located not only in the mammalian central nervous
system (CNS) cells but also in the peripheral nervous system [9], being involved in
the mediation of various physiological processes in the body. It is currently known
that there are four types of imidazoline receptors: I1, I2, I3, I4 (non I1-non I2), from
which the first three have been mostly studied [10].
It has been emphasized that these receptors play an essential role in cell prolif-
eration, regulation of adipose tissue formation, body temperature maintenance,
mediation of gastrointestinal motility, neuroprotection, inflammation, nociceptive
sensitivity, and some neurological or psychiatric disorders (such as depression)
[11]. Moreover, it is known that these imidazoline receptor subtypes exert control
over the activity of the hypothalamic-pituitary-adrenal and noradrenergic axis
[12, 13].
A number of different endogenous ligands have been characterized: agmatine,
the best known and largely studied, harmane and harmalane (derivatives of the
beta-carboline group), and the newly discovered ribotide (acetic acid imidazole).
Agmatine, the potent neurotransmitter of the imidazoline system, has an important
role in the mediation of body’s response to stress, analgesia, drug addiction, and
abstinence syndrome, in modulation of seizures development, and in
neuroprotection [14, 15].
Endogenous agmatine is produced in response to stress (in conditions of ische-
mia, prolonged exposure to cold) and/or to inflammation [16]. It is assumed that
agmatine is also an effective neurotransmitter, due to its concentration in the brain
similar to classical neurotransmitters [17, 18].
Literature data have revealed that agmatine stimulates the activity of endothelial
nitric oxide synthase [16], this effect being also proved by its level in the rat brain
after cerebral ischemia [19, 20].
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Along with evidence of its neuromodulatory and neuroprotective properties, there
are numerous preclinical studies demonstrating the beneficial effects of exogenous
administration of agmatine in depression, anxiety, hypoxic ischemia, pain, morphine
tolerance, memory impairment, Parkinson’s disease, Alzheimer’s disease, epilepsy,
and other related conditions with traumatic brain injuries (Figure 1) [21–23]. All
these are arguments in favor of the potential of agmatine as a new pharmacological
agent for the treatment of various neurological diseases and NDDs [24].
3. The involvement of the imidazoline system in the mediation of
cognitive functions
Electrophysiological studies involving various brain areas, performed on labora-
tory animals with experimentally induced cerebral alterations, have demonstrated
the neurotropic effects of agmatine [25].
In vitro experimental researches have shown that activation of I2 receptors via the
agmatine endogenous ligand exerts neuroprotective effects by increasing the
Figure 1.
Neuroprotective effects of agmatine and their first discovery.
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Neuroprotection
expression of glial fibrillary acidic protein in astrocyte cultures and by inhibiting
MAO activity [26, 27]. Moreover, the beneficial effects of agmatine have been
observed on ischemic-hypoxic lesions, on glutamate-induced neurotoxicity by acti-
vating the imidazoline receptors [28, 29]. It was also demonstrated that agmatine
administration improves learning activity andmemory of rats in experimental models
of Alzheimer’s disease and streptozotocin-induced type two diabetes mellitus [22, 30].
Other experimental investigations highlight the neuroprotective effect of intra-
nasal administration of agmatine in elderly female rats, with a significant improve-
ment of neurological status and increase of survival rate [28, 29].
The neuroprotective effects of agmatine on the morphological changes deter-
mined by repeated induced stress on medial prefrontal cortex and hippocampus of
the rat were also investigated [31]. It was emphasized that under constant stress
conditions, morphological alterations of the brain are associated with the reduction
of endogenous agmatine levels [measured by high-performance liquid chromatog-
raphy (HPLC)] and with an increase of arginine-decarboxylase level in the pre-
frontal cortex, hippocampus, striatum, and hypothalamus [32].
The exogenous administration of agmatine lowers brain morphological impair-
ment, suggesting thus its neuroprotective effects against structural changes in the
rat brain, under recurrent stress circumstances [32]. Moreover, elevated levels of
agmatine have been evidenced in the blood, cortex, hippocampus, and hypothala-
mus, immediately after brain hypoxic ischemia. Other studies emphasize the
neuroprotective influences of agmatine, highlighted by the increase of its brain
levels, in rats subjected to prolonged cold-exposure stress conditions [33].
The neuroprotective potential of agmatine was also highlighted in the experi-
mental model of 1-methyl-4-phenyltetrahydropyridine (MPTP)-induced
Parkinson’s disease in mice [29]. The use of agmatine attenuates the loss of cellular
dopamine from the black substance and repeated treatment improves short-term
memory impairment induced by MPTP in elderly mice. The behavioral benefits of
agmatine are associated with the decrease in MPTP-induced glutamate capture in
the hippocampal area, suggesting thus its involvement in modulation of glutamate
recapture, the possible mechanisms responsible for lowering glutamate extracellular
levels, thereby alleviating its neurotoxicity [29].
It is known that alteration of spatial memory in Parkinson’s disease and schizo-
phrenia is attributed to several factors, including hypofunction of glutamate and
reduction of hippocampal volume [34]. Literature data report that the administration
of the N-methyl-D-aspartate (NMDA) receptor antagonists (phencyclidine, also
coded MK801) frequently impairs the late alternation performance in a standardized
behavioral model of cognitive functions alteration similar to schizophrenia in labora-
tory animals [34]. The use of the glutamate/NMDA receptor antagonist phencyclidine
induces a spectrum of behavioral, neurochemical, and anatomical changes,
manifested by locomotor hyperactivity, motor-negative deficits, and cognition alter-
ations (with memory impairment and visual attention) in laboratory animals. This
substance was used to induce the experimental schizophrenia in laboratory animals
[35, 36]. Agmatine attenuates cognitive and behavioral deficiency in rats with exper-
imental phencyclidine-induced schizophrenic manifestations [37].
The effects of agmatine on memory alterations similar to those found in
Alzheimer’s disease have been evaluated in rats; in the pathogenesis of this degen-
erative disorder (which causes cognitive deficits in rodents), the fragment beta
amyloid Aβ2 25–35 plays an essential role. Studies have shown that agmatine signif-
icantly reduces the alterations in memory and spatial learning induced by the beta
amyloid Aβ2 25–35 fragment (the neurotoxic component of beta amyloid Aβ 1–42)
in various behavioral experimental models, such as: the swimming test, the radial
arm maze test, and the object recognition test [38].
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It has been revealed that agmatine diminishes the activation of hippocampal
caspase-3 (the early indicator of neuronal apoptosis) and prevents the alteration of
spatial memory induced by lipopolysaccharides, in the swimming test in rat [39],
suggesting its neuroprotective effects.
The neurotropic activity of agmatine has been also evidenced in the structural
and cognitive alterations after the administration of NMDA (N-methyl-D-
aspartate) in rats [40]. The use of high performance liquid chromatography
(HPLC) and electrochemical detection allowed highlighting that the treatment with
NMDA is associated with low concentrations of monoamines (epinephrine, norepi-
nephrine, dopamine, and serotonin) in rat PC12 cells [29, 40]. In this experimental
model (swimming test), agmatine protects against NMDA-induced PC12 cell
lesions, augmenting the levels of epinephrine, norepinephrine, and dopamine, but
not influencing serotonin values, together with lowering intracellular Ca2+ overload.
These results indicate that the neuroprotective action of agmatine may be related to
NMDA-receptor modulation and/or to controlling the decrease in monoamine con-
tent and NMDA-induced intracellular Ca2+ overload [40].
Immunohistochemical studies and electrophysiological investigations performed
on the brain have validated the neuroprotective actions of both imidazoline recep-
tor antagonists idazoxan and efaroxan in rats with cerebral damages caused by the
use of quinolinic acid [41], and also in mice with experimentally induced autoim-
mune encephalomyelitis, confirming the improvement of brain structural alter-
ations and blood brain barrier lesions curtail [42].
A new (+)2-(ethyl-2,3-dihydrobenzofuranyl)-2-imidazoline derivative—
dexefaroxan—the (+) enantiomer of efaroxan has been characterized. It has a
potent and selective α2 antagonist activity, with facultative effects on cognitive
functions in the passive avoidance test in rats with memory-deficiency induced by
scopolamine, diazepam, or by the 2-adrenergic agonist UK 14,304.
Dexefaroxan improves the cognitive performances in the passive avoidance test,
facilitates spatial memory in the Morris swimming test in rats, and increases the
object recognition ability in the specific behavioral test in mice [43, 44]. It has also
proved to ameliorate the animal’s memory deficits in these tests, particularly by
attenuation of spontaneous memory loss, and to improve their spatial recognition
ability, rather than through the acquisition skills or various other non-cognitive
effects.
After subcutaneous administration of dexefaroxan, its pharmacodynamic effects
persist for about 21–25 days, indicating that tolerance does not occur during
prolonged treatment. Moreover, it was emphasized that dexefaroxan exerts protec-
tive effects on the spatial memory deficit caused by cortical devascularization in the
Morris swimming test in rats [43].
Dexefaroxan has also been shown to exhibit neuroprotective effects on the de-
vascularization-induced neurodegeneration, to ameliorate the structural changes in
the hippocampus, and to remove the cognitive deficits induced by cerebral ischemia
in rats [45, 46]. Its neuroprotective effects were present also in the excitotoxic
lesions produced at the region of the basal magnocellular nucleus, increasing the
olfactory discriminative capacity of rats, suggesting thus the possibility of its use in
the treatment of memory disturbances in Alzheimer’s disease [43].
Studies performed on genetically modified animals revealed that dexefaroxan
improves cognitive performance in knockout mice with Alzheimer’s disease [47].
Literature data regarding the neuroprotective action of imidazoline agonist and
antagonist agents in human studies are only few, and the mechanisms involved in
these effects are not completely deciphered.
Some investigations suggested that agmatine manifests protective activity
against brain cell injury in different in vivo models of Parkinson’s disease, as well as
18
Neuroprotection
in vitro studies, performed on human-derived dopaminergic neuroblastoma cell
lines. It was postulated that the neuromodulatory properties of agmatine are related
to the protective effects on the dopaminergic neurons, to NMDA receptor blocking,
and to the decrease in oxidative stress, due to the inhibition of nitric oxide synthase
(NOS) activity [48, 23].
Other clinical trials highlighted that the treatment with agmatine was associated
with cytoprotective actions, in patients with spinal cord injury, proved by lessening
the glial weal construction, decreasing the collagen scar zone, relieving the neuronal
alterations, and recovering remyelination [49]. Moreover, the beneficial effects of
agmatine have been demonstrated in various CNS lesions such as: cerebrovascular
accident, brain trauma, neuropathic pain, lumbar degenerative disc disease, and
different other types of neuropathy [50–52].
The administration of dexmedetomidine has also shown neuroprotective effects
in humans with acute cerebral lesions [53].
In patients with dementia due to brain frontal lesions, idazoxan alleviates atten-
tional and executive dysfunctions evoked by classical cognitive function tests [54].
4. The interrelation between the adrenergic and the imidazoline
systems in the mediation of cognitive functions
Clonidine, both a non-specific α2 adrenergic and imidazoline receptor agonist,
decreases the cognitive function alterations induced by phencyclidine and MK801,
facilitating spatial memory in the radial arm maze test in rats [35], but does not
influence the behavioral and cognitive deficits in the experimental NMDA-induced
excitotoxic dorsal hippocampal lesions [35]. Such findings indicate that clonidine
improves memory alterations caused by glutamate hypofunction, but not by hip-
pocampal injury, implying that multiple and distinct mechanisms are involved in
the development of memory disorders.
The administration of the α2 adrenergic receptor agonist clonidine or guanfacine
prevents some of the behavioral effects of NMDA antagonists, proving that the
monoaminergic system mediates a number of aspects of the cognitive deficit. Clo-
nidine and guanfacine improve the lack of visual attention and spatial memory
induced by phencyclidine in rats [34, 36]. It was demonstrated that low doses of
clonidine recover the animal’s ability to accurately choose the object and prevent the
performance deficit induced by phencyclidine. At high doses, clonidine decreases
the response time and induces a lack of the choice accuracy. These results indicate
that clonidine treatment can alleviate phencyclidine-induced deficit of attention
and of working memory, probably by preventing some of the neurochemical and
anatomical effects of this psychotomimetic drug [34].
On the other hand, the use of only the selective α2 adrenergic receptor antago-
nist does not impair the animal’s spatial memory, but dramatically aggravates the
phencyclidine-induced memory deficit [36]. These data demonstrate that α2
adrenergic receptors mediate the inhibition of spatial memory disturbances,
suggesting their important role in cognitive deficits associated to NMDA receptor
hypofunction [34, 36].
The role of moxonidine (an α2 adrenergic imidazoline I1 receptor agonist) on
cognitive function in rats with Huntington’s disease experimentally induced with 3-
nitropropionic acid (3-NPA) was investigated in the Morris swimming test and in
the elevated plus maze test. The administration of 3-NPA induces degenerative
brain damage, progressive motor dysfunction, loss of grip force, emotional distur-
bances, weight loss, anxiety, and impairment of learning activity and memory. An
increase in cerebral acetylcholinesterase level, enhancement of oxidative stress, and
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impairment of the activity of mitochondrial enzyme complexes I, II, and IV were
also noted [28]. The treatment with moxonidine resulted in the alleviation of dis-
turbances caused on animal weight, motor activity, gripping ability, anxiety,
impairment of learning ability and memory, and biochemical disturbances, thus
indicating that substances modifying the activity of I1 receptors may be potential
pharmacological agents for the treatment of degenerative brain disorders [55].
The effects of clonidine have also been evaluated in mice with subacute brain
ischemia obtained after permanent ligation of common carotid arteries. The subse-
quent brain damages consisted of expansion of cerebral infarction areas, assessed by
computed tomography scans. This experimentally induced chronic cerebral
hypoperfusion was associated with a significant impairment of animal’s learning
ability and memory in the Morris swimming test [25, 28]. Subacute treatment with
clonidine for 7 days increases the expression of neuronal nuclei, glutamic acid-
decarboxylase-67, and gamma-aminobutyric acid (GABA) B receptor (GABAB1) in
hippocampal subregion cornu amonis (CA1) but does not influence the level of
these elements in the hippocampal area CA3, nor in the dentate gyrus. These data
support the idea that clonidine exerts neuroprotective effects on chronic cerebral
ischemic lesions, by regulating GABAB1 receptors and the activity of glutamic acid-
decarboxylase-67 [25].
Additionally, the decrease in superoxide dismutase (SOD), catalase (CAT), and
glutathione levels as well as the increase of both malondialdehyde (MDA) level and
cerebral acetylcholinesterase activity were noted in animals with brain ischemic
lesions [28].
Both moxonidine and clonidine have shown a decrease in histopathological
changes, oxidative stress, central cholinesterase activity, as well as a reduction in
memory disturbances and learning deficits in mice with vascular dementia induced
by subacute ischemia after permanent bilateral cerebral artery ligation [28, 40].
In vitro cell culture studies from the rat frontal cortex with glutamate-induced
neurotoxicity revealed the partial neuroprotective effects of moxonidine, with a
significant decrease in the number of dead cells [26]. Moxonidine has shown bene-
ficial effects on cerebral spasm in an experimental rabbit model of subarachnoid
hemorrhage [40, 56].
5. The interrelations between the imidazoline system and the oxidative
stress in the mediation of cognitive functions
Different pathological conditions of the body, as well as the physiological pro-
cess of aging, can cause cognitive impairment and free oxygen radicals production,
being responsible for abnormal functioning and cell death. Subsequently, a new
idea has emerged claiming that nitric oxide (NO), along with the free radicals, plays
a key role in the aging process, due to neurotoxic effects on the brain exerted by its
excessive levels [57]. Nitric oxide is generated from L-arginine under the action of
nitric oxide synthase (NOS). The three isoforms of NOS have different roles in the
body: neuronal NOS (nNOS) is responsible for synaptic plasticity, learning and
memory processes; endothelial NOS (eNOS) provides stabilization and regulation
of vascular micro-environment and contributes to neuroplasticity [58]; and induc-
ible NOS (iNOS) is involved in various pathophysiological conditions [57].
Numerous experimental researches reveal that NOS activity is significantly ele-
vated in the brain of elderly rats, being associated with existing cognitive alterations
[57, 59]. Mediated by the competitive inhibition of nNOS and iNOS, and correlated
with the stimulation of NOS, agmatine contributes to the improvement of cognitive
functions [19, 60, 61], while exhibiting neuroprotective effects [38, 39].
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Literature data have shown that agmatine eliminates neuroinflammation and
lipopolysaccharide-induced memory impairment (which is known to stimulate
iNOS activity and, implicitly, the NO production) in laboratory animals. It prevents
cognitive alterations, probably as a result of inhibition of iNOS activity [39]. Other
researchers have disproved these results by showing that agmatine can cause cog-
nitive impairment due to the inhibition of NMDA receptors and of NO, important
elements in the modulation of learning and memory processes [62, 63].
On the other hand, it is known that the central cholinergic system plays a crucial
role in the mediation of cognitive functions. Cognitive deficits have been induced in
laboratory animals by using an anticholinergic agent, scopolamine, its administra-
tion producing a significant reduction in NOS activity, and an increase in arginase
activity, of L-ornithine and putrescine levels in the hippocampus [51]. It has been
observed that agmatine eliminates the scopolamine-induced alterations of memory
and learning capacity [64, 65].
Although glutamatergic activity is required for cognitive processes, it is assumed
that the increase of glutamate levels or of NMDA activity would also be responsible
for the scopolamine-induced cognitive disturbances [66].
Knowing that agmatine blocks NMDA receptors and also interferes with the
pathways of NO, NOS, and L-arginine, it was assumed that the removal of
scopolamine-induced cognitive deficits can be attributed to its modulating effect on
NO/NOS activity, on L-arginine, and also to the antagonization of NMDA recep-
tors, with subsequent suppression of excessive glutamatergic activity [61, 65].
Abnormal release and disturbances of neuromodulatory activities due to varia-
tion in cerebral agmatine levels may be correlated to different CNS diseases (such as
schizophrenia). Interactions of agmatine with other central neurotransmitter sys-
tems (such as glutamatergic and nitrergic) appear to be particularly important in
the pathophysiological mechanisms of CNS disorders associated with brain damage
and cognitive functions deficit.
6. The opioid system
Neurodegeneration can be caused by chronic disease progression or by acute
injury (cerebral ischemia—stroke or trauma) [67]. Ischemic stroke represents a
vascular ailment with neurological consequences produced by the obstruction of the
arteries in a part of the brain, therefore by blood supply privation [68]. Stroke can
determine long-term neurological and psychiatric impairments, its therapy being
focused on confining secondary injury processes [67].
In a recent review article, Chamorro presented that ischemic stroke is “the first
cause of permanent disability in adult people, the second single most frequent cause
of death for people older than 60 years, the second most common cause of demen-
tia, representing approximately 3% to 7% of the total health-care expenditure in
high income countries” [69].
A superpose of pathologies in different neurological disorders was proposed
since NDDs and ischemic stroke are frequently concomitant, hence the
neuroprotective therapy could be similar [70].
Opioids are substances with morphine-like action binding to specific opioid
receptors (ORs). In the early 1990s, three important opioid receptor families
[μ (MOR), κ (KOR), and δ (DOR)] were identified, and in 1994 another opioid
receptor was discovered [nociceptin, orphanin FQ receptor (NOP), or the opioid
receptor-like orphan receptor (ORL)]. ORs are found in the nervous system, lungs,
heart, liver, and gastrointestinal and reproductive tracts. They have been inten-
sively studied and it was emphasized that they not only are related to
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antinociceptive action, but also have a role in cell proliferation, ionic homeostasis,
emotional response, immune function, epileptic seizures, feeding, obesity, respira-
tory and cardiovascular control, hibernation, and neuroprotection [71, 72].
In the last decades, researches have pointed out that the opioid system can be
promising to get neuroprotective treatment in the event of stroke, through OR
agonists at lower doses, to avoid tolerance and/or physical dependency. DOR ago-
nists followed by KOR agonists have revealed the most intense neuroprotective
efficacy [64]. Major OR agonists tested for neuroprotection are listed in Table 2
[71, 72].
DOR activation is beneficial against ischemic, hypoxic, and excitotoxic injuries
[73]; recent studies promote DOR and especially DADLE (an analog of endogenous
delta-opioid enkephalin) as promising targets for treating NDDs like stroke and PD
[74–76].
DADLE alleviates apoptotic pathways, supports not only cell survival of periph-
eral organs (such as lung, heart, kidney, and liver) but also neuronal survival, and
protects neurons and glial cells from ischemia-induced cell death [76–78].
In a cellular model of PD, DADLE administration augmented cell survivability
with concurrent downregulation of the unfolded protein response stress sensors and
protein aggregates [79].
Findings from a rat middle cerebral artery occlusion (MCAO) stroke model
proposed that neuroprotection of DADLE treatment was based on the activation of
PI3K-Akt pathway by reducing nerve cell apoptosis [80].
Non-selective opioid receptor agonists were also tested: LYS739 (fluorinated
enkephalin-fentanyl derivative) and the most promising compound—biphalin—
which proved to be effective both in vitro and in vivo stroke models [72].
The latter is a dimeric enkephalin analog (Tyr-D-Ala-Gly-Phe-NH-)2 with high
potency and affinity for MOR and DOR and low affinity for KOR. Biphalin crosses
blood-brain barrier reaching spinal and supraspinal sites expressing OR and pro-
duces less physical dependence and tolerance compared to morphine [72, 81–84].
Opioid receptor Agonist












Endorphin 1 and 2 (EM 1/2),
Morphine
Table 2.
Opioid receptors and their agonists tested for neuroprotective action.
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Different studies using a mouse MCAO stroke model reported that biphalin
reduced brain edema and infarction, ROS production, and NMDA-induced
excitotoxicity. It also increased locomotor activities and neurological score after
stroke resembled to saline-treated animals [72, 81, 85, 86]. Biphalin notably dimin-
ished penumbral expression of Na+, K+, 2Cl cotransporter (NKCC), and the trans-
location of the conventional isoforms of protein kinase C [81].
It has been hypothesized that biphalin’s neuroprotective effects are more intense
compared to subtype-selective agonists due to concomitant activation of the three
types of OR [72, 85].
7. Conclusion
Various pharmacological substances influencing the pathways of the main neu-
rotransmitters have confirmed valuable effects in neurogenesis and
neuroprotection, being validated in different in vitro researches and in vivo experi-
mental animal models of limited or extensive ischemic brain lesions.
Deciphering the roles of the neurotransmitters in central nervous system activity
other than the signaling function will represent a starting point to deepen the
knowledge about the complex mechanisms of the brain functions and to obtain new
agents useful for protection of ischemic neurons and for preventing their irrevers-
ible damage.
23
Current Therapeutic Approaches from Imidazoline and Opioid Receptors Modulators…
DOI: http://dx.doi.org/10.5772/intechopen.81951
antinociceptive action, but also have a role in cell proliferation, ionic homeostasis,
emotional response, immune function, epileptic seizures, feeding, obesity, respira-
tory and cardiovascular control, hibernation, and neuroprotection [71, 72].
In the last decades, researches have pointed out that the opioid system can be
promising to get neuroprotective treatment in the event of stroke, through OR
agonists at lower doses, to avoid tolerance and/or physical dependency. DOR ago-
nists followed by KOR agonists have revealed the most intense neuroprotective
efficacy [64]. Major OR agonists tested for neuroprotection are listed in Table 2
[71, 72].
DOR activation is beneficial against ischemic, hypoxic, and excitotoxic injuries
[73]; recent studies promote DOR and especially DADLE (an analog of endogenous
delta-opioid enkephalin) as promising targets for treating NDDs like stroke and PD
[74–76].
DADLE alleviates apoptotic pathways, supports not only cell survival of periph-
eral organs (such as lung, heart, kidney, and liver) but also neuronal survival, and
protects neurons and glial cells from ischemia-induced cell death [76–78].
In a cellular model of PD, DADLE administration augmented cell survivability
with concurrent downregulation of the unfolded protein response stress sensors and
protein aggregates [79].
Findings from a rat middle cerebral artery occlusion (MCAO) stroke model
proposed that neuroprotection of DADLE treatment was based on the activation of
PI3K-Akt pathway by reducing nerve cell apoptosis [80].
Non-selective opioid receptor agonists were also tested: LYS739 (fluorinated
enkephalin-fentanyl derivative) and the most promising compound—biphalin—
which proved to be effective both in vitro and in vivo stroke models [72].
The latter is a dimeric enkephalin analog (Tyr-D-Ala-Gly-Phe-NH-)2 with high
potency and affinity for MOR and DOR and low affinity for KOR. Biphalin crosses
blood-brain barrier reaching spinal and supraspinal sites expressing OR and pro-
duces less physical dependence and tolerance compared to morphine [72, 81–84].
Opioid receptor Agonist












Endorphin 1 and 2 (EM 1/2),
Morphine
Table 2.
Opioid receptors and their agonists tested for neuroprotective action.
22
Neuroprotection
Different studies using a mouse MCAO stroke model reported that biphalin
reduced brain edema and infarction, ROS production, and NMDA-induced
excitotoxicity. It also increased locomotor activities and neurological score after
stroke resembled to saline-treated animals [72, 81, 85, 86]. Biphalin notably dimin-
ished penumbral expression of Na+, K+, 2Cl cotransporter (NKCC), and the trans-
location of the conventional isoforms of protein kinase C [81].
It has been hypothesized that biphalin’s neuroprotective effects are more intense
compared to subtype-selective agonists due to concomitant activation of the three
types of OR [72, 85].
7. Conclusion
Various pharmacological substances influencing the pathways of the main neu-
rotransmitters have confirmed valuable effects in neurogenesis and
neuroprotection, being validated in different in vitro researches and in vivo experi-
mental animal models of limited or extensive ischemic brain lesions.
Deciphering the roles of the neurotransmitters in central nervous system activity
other than the signaling function will represent a starting point to deepen the
knowledge about the complex mechanisms of the brain functions and to obtain new
agents useful for protection of ischemic neurons and for preventing their irrevers-
ible damage.
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Abstract
Adenosine is a neuromodulator that regulates the body’s response to dopamine 
and another neurotransmitter in the brain that is responsible for motoric, emotion, 
learning, and memory function. Adenosine is a G-protein-coupled receptor and 
has four subtypes, which are A1, A2A, A2B, and A3. Adenosine A2A is located in the 
striatum of the brain. Antagonist interferes with GABA releasing, modulates acetyl-
choline and releases dopamine, and also facilitates dopamine receptor’s signaling. 
Therefore, it can reduce motoric symptoms in Parkinson’s disease. Adenosine A2A 
antagonist is also believed to have neuroprotective effects. Several compounds have 
been reported and have undergone clinical test as selective adenosine A2A antago-
nists, including istradefylline, preladenant, tozadenant, vipadenant, ST-1535, and 
SYN-115. Nonselective adenosine A2A antagonists from natural compounds are 
caffeine and theophylline.
Keywords: adenosine A2A, selective adenosine A2A antagonists, Parkinson’s disease, 
neuroprotective, natural compounds
1. Introduction
Adenosine is a neuromodulator that coordinates responses to dopamine and 
other neurotransmitters in areas of the brain responsible for motor function, mood, 
learning, and memory [1]. Adenosine consists of four receptor subtypes: A1, A2A, 
A2B, and A3 belonging to the superfamily of G-protein-coupled receptor. Adenosine 
A1 and A3 receptors are coupled to inhibitory G proteins, while A2A and A2B recep-
tors are coupled to stimulatory G proteins [2].
Adenosine A1 receptor can be found in adipose tissue, heart muscle, and inflam-
matory cells. The receptor mostly expressed by the central nervous system such 
as neocortex, cerebellum, hippocampus, and dorsal horn of the spinal cord [3]. 
The pre- and postsynaptic nerve terminals, mast cells, airway smooth muscle, and 
circulating leukocytes are the places where adenosine A2 receptor can be found. As 
the more widely dispersed receptor, adenosine A2 is divided into two receptors on 
the basis of high- and low-affinity for adenosine, A2A and A2B [4]. Striatal neurons 
are where the adenosine A2A are highly enriched; however its lower levels can also be 
found in glial cells and neurons outside the striatum [5]. The adenosine A2B recep-
tors are highly expressed in the gastrointestinal tract, bladder, lung, and on mast 
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Basal ganglia circuitry in normal conditions.
cells. The most widely dispersed receptor is the A3 receptor which can be found in 
the kidney, testis, lung, mast cells, eosinophils, neutrophils, heart, and the brain 
cortex [4].
Adenosine A2A receptors are found to be concentrates in GABAergic medium-
sized spiny neurons in the dopamine-rich regions of the brain. The protein trans-
lated in the adenosine A2A is carried by many other tissues such as blood vessels, 
endothelial, lymphoid cells, smooth muscle cells, and several neurons in sympa-
thetic and parasympathetic systems [6]. Therefore, the dispersion of adenosine 
A2A is not limited to the medium spiny neurons in the basal ganglia. It stimulates 
the modulation of cAMP production and increases the level of adenylyl cyclase. 
This receptor is essential in giving the medium of vasodilation of coronary arteries 
which then supports the combination of new blood vessels and giving protection 
for tissues from indirect inflammatory damage [7]. The role of the A2A in the brain 
includes influencing the activity within the indirect pathway of the basal ganglia. 
The A2A has complicated actions because it colocalizes and is physically combined 
with other unrelated G-protein-coupled receptors. Therefore, it can form heterodi-
mers such as dopamine D2/A2A, and D3/A2A, cannabinoid CB1/A2A, and glutamate 
mGluR5/A2A, as well as CB1/A2A/D2 heterotrimers [7].
The pathways which give signals used by the A2A receptor depend on the location 
of the cell and tissue, the specific G protein which couples it, and the signaling in 
the cell. The brain also carries the A2A receptor in which it plays an important role 
in regulating the glutamate and releasing the dopamine [8]. In the striatopallidal 
neurons, dopamine D2 receptors are colocalized with adenosine A2A receptors. 
Adenosine A2A receptor activity that mediates stimulation and D2 receptors that 
mediate inhibition in the striatopallidal pathway are balanced [9]. The adenosine A2A 
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likely affects motor activity by acting at different levels of the basal ganglia network. 
The basal ganglia comprise the striatum (putamen), the globus pallidus externa 
(GPe), the globus pallidus interna (GPi), substantia nigra pars compacta (SNc), 
substantia nigra reticulata (SNr), and the subthalamic nucleus (STN). The striatum 
is represented by medium-sized spiny projection neurons (MSNs), accounting 
for almost 95% of striatal neurons and using γ-aminobutyric acid (GABA) as 
neurotransmitter. The GABAergic spiny neurons give rise to the two main striatal 
efferent circuits: the striatonigral and the striatopallidal pathway. The neurons of the 
striatonigral (direct) pathway contain the neuropeptide substance P and dynorphin 
and mainly express D1 receptors; this pathway directly projects from the striatum 
to the GPi/SNr. The neurons of the striatopallidal (indirect) pathway containing the 
neuropeptide, enkephalin (ENK), predominantly express D2 receptors; this circuit 
connects the striatum with the GPi/SNr via synaptic connections in the GPe and 
STN in Figure 1. Dopamine modulates motor coordination and fine movements 
by facilitating the action of the direct pathway on stimulatory D1 receptors and by 
inhibiting indirect pathway function acting on inhibitory D2 receptors [10].
The adenosine A2A receptor has agonists and antagonists of which the roles are 
potentiating and inhibiting, respectively. The D2 receptor agonist has effects on 
motor activity, the releasing of neurotransmitter, and the expression of striatal of 
c-Fos, a factor of transcription which is used as neuronal activity’s indirect marker 
[11]. The adenosine A2A receptor has a key role in regulating the striatal dopaminer-
gic neurotransmission which produces substances that are valuable to treat neuro-
logical disorders that are relevant with dopaminergic dysfunction.
The topology of G-protein-coupled receptor is displayed in the structure of the 
adenosine A2A receptor. These receptors have a central core which consists of seven 
Figure 2. 
Crystal structure of the adenosine A2A receptor (4EIY) shown in the membrane structure. The extracellular 
and intracellular parts of the membrane are shown in red and blue beads, respectively. The disorder residues of 
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transmembrane helices (7TM). Each of the TM is mainly α-helical and consists of 
20–27 amino acids. Three intracellular (IL1, IL2, and IL3) and three extracellular 
(EL1, EL2, and EL3) loops connect each of the TM domain. A short helix TM8 runs 
parallel to the cytoplasmic surface of the membrane. The adenosine A2A recep-
tor has differences in length and N-terminal extracellular domain function, their 
domain of C-terminal intracellular, and their loops of intracellular/extracellular. 
These differences are shown in Figure 2.
2. The role of adenosine A2A in Parkinson’s disease
Parkinson’s disease (PD) is a chronic neurodegenerative disorder in the brain, 
marked by motoric symptoms [12]. The motoric symptoms in PD are resting 
tremor, rigidity, bradykinesia, and postural disorder. Besides motoric symptoms, 
PD also has non-motoric symptoms such as depression, hallucination, sleeping 
disorder, and decreasing cognitive and sensory functions. The main pathological 
characteristic of PD is the loss of dopaminergic neurons in substantia nigra pars 
compacta, a region in the brain that controls all the body movement and forms the 
dopamine. The development of PD also includes the formation of Lewy body, a 
deposit of cytoplasmic, eosinophilic neuronal inclusions, composed of the presyn-
aptic protein α-synuclein [13, 14].
The current therapy of PD is targeted at dopamine replacement, thereby 
decreasing the motor symptoms. It includes precursor of dopamine (levodopa), 
dopamine agonists [15, 16] monoamine oxidase type B (MAO-B) inhibitors [17], 
and catechol-O-methyltransferase (COMT) inhibitors [17, 18]. These agents 
produce undesirable side effects such as on-off effects, hallucinations, and dyskine-
sia. These effects get more severe as the treatment continued. The efficacy of these 
agents is also decreasing as the disease progressed [19].
Because of the undesirable side effects of dopamine replacement therapy, the 
non-dopaminergic therapy is continuously being explored. One of the approaches 
is selective adenosine A2A antagonist [20, 21]. Adenosine A2A receptors are found 
mainly in the striatum of rat [22, 23], which has similar distribution with the 
human brain [24, 25]. In the striatum, adenosine A2A receptors are colocalized 
with dopamine D2 receptors. These two receptors have opposite effect on motoric 
function [26]. The activation of adenosine A2A receptors will inhibit the signaling of 
dopamine D2 receptors, and conversely, the inhibition of signaling of adenosine A2A 
receptors will increase the activation of dopamine D2 receptors, therefore facilitat-
ing dopamine D2-mediated responses [11]. The inhibition of adenosine A2A recep-
tors showed motoric improvement in animal models of PD [27–30]. This also has 
desirable effect on long-term levodopa treatment such as decreasing the dyskinesia 
and increasing the therapeutic effect on levodopa [31, 32].
3. Adenosine A2A receptor antagonist as a neuroprotective
For years, adenosine-dopamine interactions have been investigated in order to 
observe their relevance for treatment of central nervous system (CNS) disorders 
[33]. It is assumed that adenosine A1 receptors (A1Rs) play an important role in 
neuroprotection as their activation at the onset of neuronal injury has shown to 
reduce brain damage in adult animal model. Vice versa, their blockade aggravates 
the damage. In other hand, adenosine A2 receptors (A2ARs) are shown to be 
upregulated in harmful brain conditions, and their blockade shows brain neuro-
protection in studied animals [34]. The blockade of A2ARs alleviates the long-term 
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burden of brain disorders in different neurodegenerative conditions, namely, 
ischemia, epilepsy, and Parkinson’s and Alzheimer’s disease, through its control 
on neuronal cell death [35].
A2ARs have been shown to be viable in serving as alternative non-dopaminergic 
strategy of Parkinson’s disease treatment because of their limited distribution in the 
striatum and the intense interaction between adenosine and dopamine receptors 
in the brain. A2ARs antagonists were shown to improve motor function in different 
animal models (primates and rodents), alone or co-administered with dopamino-
mimetic drugs, levodopa, or dopamine agonists [35]. Based on rigorous preclinical 
animal studies, istradefylline (KW6002) has shown its promising ability to increase 
motor activity in PD of the advanced stage in clinical phase IIB trial [36]. It became 
the first therapeutic agent developed to target A2ARs, and other similar compounds 
will be available in near future [37].
The recent meta-analysis (n = 6) suggested that 20 mg of istradefylline improves 
unified Parkinson’s disease ranking scale (UPDRS) III. Meanwhile at 40 mg per 
day, istradefylline could alleviate off time and motor symptoms derived from 
Parkinson’s disease [38]. Phase 3 study (613 randomized patients), done by Isaacson 
et al. concluded that greater reduction from baseline in total hours off time/day 
were shown at all-time points for istradefylline 20 and 40 mg/day, compared to 
placebo. However, future development is needed as the study has not yet reached 
statistical significance [39].
In the case of Parkinson’s disease, microglia has been suggested to be the most 
likely cell type to be targeted by A2ARs antagonists [40]. In vitro and in vivo studies 
showed that local neuroinflammation make glial cells (especially microglial cells) 
particularly sensitive to A2AR modulation [41]. Previous research done by Gao 
and Phillis is the first study to demonstrate nonselective A2AR antagonist action in 
reducing cerebral ischemic injury in the gerbil, following global forebrain ischemia 
[42]. After that, many studies have reported the neuroprotective of A2AR antago-
nists in different models of ischemia [43].
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that is indi-
cated by the progressive loss of memory and other cognitive functions, leading to 
dementia [44, 45]. Adenosine can control and integrate cognition and memory 
[46]. Both A1Rs and A2ARs, mainly located in synapses, control the release of 
neurotransmitters which are involved in memory or other cognitive processes  
[34, 47]. Methylxanthine was discovered to act as nonselective adenosine receptors 
antagonist. Caffeine, the most famous methylxanthine found in common bever-
ages, is the most widely consumed psychoactive drug. Maia and de Mendonca pre-
sented the first epidemiological data showing that the incidence of AD is inversely 
proportioned with coffee consumption [48]. Several other studies also show this 
inverse relationship [49–51]. Animal models also shown that caffeine intake may be 
beneficial for AD. In a study, a 6-month period of 0.3 g/L caffeine intake alleviated 
the cognitive deficits found in AD transgenic mice (APPsw). Furthermore, these 
mice culture neurons showed the reduced production of Aβ1–40 and Aβ1–42 peptides 
[52]. A2ARs antagonists and/or caffeine prophylactic and long-term neuroprotective 
process are suggested to be based on inhibition of reactive oxygen species activity, 
tau pathology, and Aβ production by neuronal cells [53].
A2ARs antagonist may also serve as antidepressants, as observed in animal model 
of antidepressants screening test done by El-Yacoubi et al. [54, 55]. In both tests, 
A2ARs antagonists prolong escape-directed behavior. Additionally, potential role as 
antidepressants was also observed in attenuated behavioral despairs displayed in 
both tests [55]. The relation between adenosine and depression in preclinical models 
was obtained from the genetic manipulation model of A2AR. Genetic depletion 
of A2ARs resulted in antidepressant-like phenotype in animal models [55]. The 
Neuroprotection
34
transmembrane helices (7TM). Each of the TM is mainly α-helical and consists of 
20–27 amino acids. Three intracellular (IL1, IL2, and IL3) and three extracellular 
(EL1, EL2, and EL3) loops connect each of the TM domain. A short helix TM8 runs 
parallel to the cytoplasmic surface of the membrane. The adenosine A2A recep-
tor has differences in length and N-terminal extracellular domain function, their 
domain of C-terminal intracellular, and their loops of intracellular/extracellular. 
These differences are shown in Figure 2.
2. The role of adenosine A2A in Parkinson’s disease
Parkinson’s disease (PD) is a chronic neurodegenerative disorder in the brain, 
marked by motoric symptoms [12]. The motoric symptoms in PD are resting 
tremor, rigidity, bradykinesia, and postural disorder. Besides motoric symptoms, 
PD also has non-motoric symptoms such as depression, hallucination, sleeping 
disorder, and decreasing cognitive and sensory functions. The main pathological 
characteristic of PD is the loss of dopaminergic neurons in substantia nigra pars 
compacta, a region in the brain that controls all the body movement and forms the 
dopamine. The development of PD also includes the formation of Lewy body, a 
deposit of cytoplasmic, eosinophilic neuronal inclusions, composed of the presyn-
aptic protein α-synuclein [13, 14].
The current therapy of PD is targeted at dopamine replacement, thereby 
decreasing the motor symptoms. It includes precursor of dopamine (levodopa), 
dopamine agonists [15, 16] monoamine oxidase type B (MAO-B) inhibitors [17], 
and catechol-O-methyltransferase (COMT) inhibitors [17, 18]. These agents 
produce undesirable side effects such as on-off effects, hallucinations, and dyskine-
sia. These effects get more severe as the treatment continued. The efficacy of these 
agents is also decreasing as the disease progressed [19].
Because of the undesirable side effects of dopamine replacement therapy, the 
non-dopaminergic therapy is continuously being explored. One of the approaches 
is selective adenosine A2A antagonist [20, 21]. Adenosine A2A receptors are found 
mainly in the striatum of rat [22, 23], which has similar distribution with the 
human brain [24, 25]. In the striatum, adenosine A2A receptors are colocalized 
with dopamine D2 receptors. These two receptors have opposite effect on motoric 
function [26]. The activation of adenosine A2A receptors will inhibit the signaling of 
dopamine D2 receptors, and conversely, the inhibition of signaling of adenosine A2A 
receptors will increase the activation of dopamine D2 receptors, therefore facilitat-
ing dopamine D2-mediated responses [11]. The inhibition of adenosine A2A recep-
tors showed motoric improvement in animal models of PD [27–30]. This also has 
desirable effect on long-term levodopa treatment such as decreasing the dyskinesia 
and increasing the therapeutic effect on levodopa [31, 32].
3. Adenosine A2A receptor antagonist as a neuroprotective
For years, adenosine-dopamine interactions have been investigated in order to 
observe their relevance for treatment of central nervous system (CNS) disorders 
[33]. It is assumed that adenosine A1 receptors (A1Rs) play an important role in 
neuroprotection as their activation at the onset of neuronal injury has shown to 
reduce brain damage in adult animal model. Vice versa, their blockade aggravates 
the damage. In other hand, adenosine A2 receptors (A2ARs) are shown to be 
upregulated in harmful brain conditions, and their blockade shows brain neuro-
protection in studied animals [34]. The blockade of A2ARs alleviates the long-term 
35
The Role and Development of the Antagonist of Adenosine A2A in Parkinson’s Disease
DOI: http://dx.doi.org/10.5772/intechopen.84272
burden of brain disorders in different neurodegenerative conditions, namely, 
ischemia, epilepsy, and Parkinson’s and Alzheimer’s disease, through its control 
on neuronal cell death [35].
A2ARs have been shown to be viable in serving as alternative non-dopaminergic 
strategy of Parkinson’s disease treatment because of their limited distribution in the 
striatum and the intense interaction between adenosine and dopamine receptors 
in the brain. A2ARs antagonists were shown to improve motor function in different 
animal models (primates and rodents), alone or co-administered with dopamino-
mimetic drugs, levodopa, or dopamine agonists [35]. Based on rigorous preclinical 
animal studies, istradefylline (KW6002) has shown its promising ability to increase 
motor activity in PD of the advanced stage in clinical phase IIB trial [36]. It became 
the first therapeutic agent developed to target A2ARs, and other similar compounds 
will be available in near future [37].
The recent meta-analysis (n = 6) suggested that 20 mg of istradefylline improves 
unified Parkinson’s disease ranking scale (UPDRS) III. Meanwhile at 40 mg per 
day, istradefylline could alleviate off time and motor symptoms derived from 
Parkinson’s disease [38]. Phase 3 study (613 randomized patients), done by Isaacson 
et al. concluded that greater reduction from baseline in total hours off time/day 
were shown at all-time points for istradefylline 20 and 40 mg/day, compared to 
placebo. However, future development is needed as the study has not yet reached 
statistical significance [39].
In the case of Parkinson’s disease, microglia has been suggested to be the most 
likely cell type to be targeted by A2ARs antagonists [40]. In vitro and in vivo studies 
showed that local neuroinflammation make glial cells (especially microglial cells) 
particularly sensitive to A2AR modulation [41]. Previous research done by Gao 
and Phillis is the first study to demonstrate nonselective A2AR antagonist action in 
reducing cerebral ischemic injury in the gerbil, following global forebrain ischemia 
[42]. After that, many studies have reported the neuroprotective of A2AR antago-
nists in different models of ischemia [43].
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder that is indi-
cated by the progressive loss of memory and other cognitive functions, leading to 
dementia [44, 45]. Adenosine can control and integrate cognition and memory 
[46]. Both A1Rs and A2ARs, mainly located in synapses, control the release of 
neurotransmitters which are involved in memory or other cognitive processes  
[34, 47]. Methylxanthine was discovered to act as nonselective adenosine receptors 
antagonist. Caffeine, the most famous methylxanthine found in common bever-
ages, is the most widely consumed psychoactive drug. Maia and de Mendonca pre-
sented the first epidemiological data showing that the incidence of AD is inversely 
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antidepressants was also observed in attenuated behavioral despairs displayed in 
both tests [55]. The relation between adenosine and depression in preclinical models 
was obtained from the genetic manipulation model of A2AR. Genetic depletion 
of A2ARs resulted in antidepressant-like phenotype in animal models [55]. The 
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A2ARs blockade also relieves stress-induced early hippocampal modifications [56]. 
However, the effect of adenosine neuromodulation system in depression is complex, 
as it has the ability to modulate several other neurotransmission systems [35].
As addressed in previous paragraphs, A2AR emerges as potential target candidate 
in various disorders. This is majorly caused by its unique interaction with D2 recep-
tors, a major psychoactive drug target. Important roles of A2AR were also observed 
in its robust neuroprotective activity, in which it mainly acts in the normalization 
of glutaminergic synapses, the control of mitochondria-induced apoptosis, and the 
control of neuroinflammation [35].
4. Current sources of the adenosine A2A antagonist
The treatment of PD currently focuses on symptom management with dopa-
minergic therapy, such as dopamine precursor L-3,4-dihydroxyphenylalanine 
(L-DOPA) (in combination with peripheral decarboxylase inhibitors) and dopa-
mine agonists [57]. Although L-DOPA is beneficial in patients with PD, with time, 
the span of the effect is shortened), the response becomes less probable, and invol-
untary muscle movements or, in a severe situation, dystonia can emerge [57]. These 
problems highlight the urgent medical need for an alternative mode of therapeutic 
intervention that can relieve the symptoms of the disorder while also allowing a 
decrease in the occurrence of side effects.
Among the non-dopaminergic therapies investigated for the treatment of PD, the 
adenosine A2A receptor antagonists show very convincingly for two main reasons: 
their selective and restricted localization in the basal ganglia circuitry and their 
interaction with dopaminergic receptors. In another word, inhibition of the interac-
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Many highly selective A2A antagonists, both xanthine and non-xanthine deriva-
tives, have been created, and some of them are being investigated as treatment for 
subjects with PD in various stage of clinical trials (Figure 3) [7, 19, 58–61]. Caffeine 
as a xanthine derivate is developed as a lead compound for the design of antagonist 
of adenosine A2A receptor [62]. Experimental model using 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism is known to be an 
evidence that caffeine have a protective effect in Parkinson’s disease [36, 63]. Some 
A2A antagonists have progressed to clinical trials by various pharmaceutical com-
panies including istradefylline [59], PBS-509, ST1535 and its metabolite ST4206, 
tozadenant, V81444, preladenant, and vipadenant [64]. Several studies of novel 
series of 2-aminoimidazo[4,5-b]pyridine-derivatives [65], arylindenopyrimidine 
[66], and bicyclic aminoquinazoline derivatives [67] as adenosine A2A antagonists 
are reported.
Various computational methods were used to study neuroprotective effect from 
adenosine A2A antagonists such as pharmacophore model [68], QSAR, molecular 
docking [69–71], and molecular dynamics [72, 73]. Orally bioavailable adenosine 
A2A receptor antagonists have been studied for its QSAR and pharmacokinetics 
properties [74].
The study of structure-kinetics relationship (SKR) is done as a complement 
to a SAR analysis at the adenosine A2A receptor. The series of 24 triazolotriazine 
derivatives showing a similar binding kinetics to the putative antagonist ZM241385 
(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)
ethyl)phenol) revealed minor affinity changes, although they varied substantially 
in their dissociation rates from the receptor [75].
5. Future direction of drug discovery of Parkinson’s disease
Various studies have been conducted in the discovery of Parkinson’s drugs 
against the target A2A receptors. The discovery of drugs assisted by computers has 
accelerated in obtaining lead compounds. Apparently, this method takes a lot of 
consideration before entering the preclinical and clinical phases. It is because this 
computational method is more able to describe the answer in preparing the next 
design. This method can also make various predictions of activities that are dif-
ficult to do in the absence of chemical compounds before they are synthesized. In 
silico prediction of various pharmacokinetic parameters and toxicity can also be 
done faster. All of these things can provide a better picture of getting a cure for 
Parkinson’s disease.
6. Conclusions
A2A receptors emerge as potential target candidate in various disorders, caused 
by its unique interaction with D2 receptors, a major psychoactive drug target. 
Various studies have been conducted in the discovery of Parkinson’s drugs against 
the target A2A receptors. In silico study brings a new approach of study with A2A 
receptors.
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Adrenergic Receptors as 
Pharmacological Targets 
for Neuroinflammation and 
Neurodegeneration in Parkinson’s 
Disease
Monika Sharma and Patrick M. Flood
Abstract
Inflammation is a key component of the dopaminergic neurodegeneration seen 
in progressive Parkinson’s disease (PD). The presence of activated glial cells, the 
participation of innate immune system, increased inflammatory molecules such 
as cytokines and chemokines, and increased oxidative stress and reactive oxygen 
species are the main neuroinflammatory characteristics present in progressive 
PD. Therapeutic targets which suppress pro-inflammatory responses by glial cells 
(mainly microglia) have been shown to be effective treatments for slowing or 
eliminating the progressive degeneration of neurons within the substantia nigra. In 
this chapter, we will detail a specific anti-inflammatory therapy using agonists to 
β2-adrenergic receptors that have been shown to be effective treatments for models 
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these neurodegenerative disorders. Recent approaches found to be effective in 
the treatment of Parkinson’s disease involve the use of anti-inflammatory agents 
and cytokines such as agonists to the β2-adrenergic receptors (β2-AR) to inhibit 
neuroinflammation and the progression of dopaminergic neurodegeneration. In 
this chapter, we will address the current understanding of therapeutic approaches 
targeting neuroinflammation linked with PD and the use of β2-AR agonists as an 
effective treatment for PD.
2.  Parkinson’s disease: a chronic neurodegenerative and 
neuroinflammatory disease
Parkinson’s disease (PD) is a progressive neurodegenerative disorder which leads 
to impaired motor skills. The major pathological feature of PD is the degeneration 
of dopaminergic (DA) neurons which project from substantia nigra (SN) to the 
striatum in the midbrain (nigro-striatal pathway) [2]. Another neuropathologi-
cal feature of PD is the cytoplasmic inclusion of misfolded α-synuclein protein in 
degenerating dopaminergic neurons called Lewy bodies [3]. The primary motor 
symptoms of PD, such as tremor, rigidity, and bradykinesia, are caused by inad-
equate formation and neurotransmission of dopamine within the nigro-striatal 
pathway [4, 5]. Dementia is reported in 28% of PD cases with the prevalence rising 
to 65% in those aged 85 years and above. Patients with PD also show non-motor-
related symptoms such as olfactory deficits, depression, cognitive deficits, sleep 
disorders, and autonomic dysfunction [6]. The majority of PD cases are idiopathic 
Parkinson’s, and the disease mechanism that ultimately causes idiopathic PD is 
largely unknown. In the remainder of the cases of PD, about 10–15% of patients do 
have a family history and those patients are referred to as having the familial form 
of PD. For these patients, their PD appears to be caused by a mutation in one of a 
few selected genes (such as SNCA, Parkin, LRRK2, DJ-1, etc.) [7, 8]. Although the 
etiology of the idiopathic form of the disease remains elusive, there are some risk 
factors associated with the development of the disease. These risk factors include 
exposure to environmental toxins, severe cranial trauma, systemic or localized 
infections, and inherited genetic risk factors. These genetic and nongenetic risk 
factors have the potential to initiate neurodegeneration and subsequent chronic 
inflammation in the brain which eventually contributes to the pathophysiology of 
PD [9]. In addition, several cellular and molecular pathways such as oxidative stress 
[10], proteosomal dysfunction [11], excitotoxicity [12], and mitochondrial dysfunc-
tion [13] have also been identified which contributes to neuronal death.
The presence of activated glial cells, increased inflammatory molecules such 
as cytokines/chemokines, and increased oxidative stress and ROS are the main 
neuroinflammatory characteristics present in PD [14]. PD is now not only charac-
terized as loss of DA-neurons and motor impairment, but also recognized to have 
an inflammatory component which plays a crucial role in the progression of the dis-
ease. Several inflammatory mediators such as TNF-α, IL-1β, ROS, and nitric oxide 
(NO), released from nonneuronal cells exacerbate the disease pathology [3, 15]. 
It has been suggested that α-synuclein released from dying neurons also activate 
the microglia via TLR2 activation [16]. Furthermore, the elevated levels of inflam-
matory cytokines such as TNF-α, IL-1β, and IL-6 have been reported in serum, 
cerebrospinal fluid (CSF), and striatum of PD patients [17]. The influx of periph-
eral macrophages has been reported in brains of patients with PD, but the role of 
these cells in disease pathology remains to be tested [18]. Additionally, activation 
and increased number of glial cells and infiltrating peripheral lymphocytes such as 
cytotoxic CD4+ and CD8+ cells in SN also support the role of adaptive immunity in 
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the etiology of the disease [8]. Overall, these studies and others suggest the contri-
bution of the immune system in the pathophysiology of PD.
3. Microglial activation and neuroinflammation in PD
Microglia originate from erythromyeloid progenitors in the yolk sac which 
migrate and differentiate during development to form the central nervous system 
(CNS). Fully differentiated microglial cells are also considered to be the resident 
macrophages of the CNS [19], although some phenotypic and functional differ-
ences between microglia and macrophages have been found [20]. Growing evidence 
suggests that the activation of microglia in CNS plays an important role in the 
pathogenesis of PD. It is not well understood how microglia activation is either 
beneficial or detrimental to the neuron or how microglial activity is regulated. It 
has been found that microglial activation is required for neuronal survival by the 
removal of toxic substances through innate immunity [21]. On the other hand, it 
has been found that over-activated microglial cells are detrimental and neurotoxic 
[22]. Research studies of post-mortem brain tissue from patients with PD and 
related parkinsonian syndromes suggest the presence of activated microglia around 
degenerating DA-neurons in the SN [23] and these activated microglia are not only 
limited to the SN but also present in extended brain areas such as hippocampus, 
putamen, trans-entorhinal cortex, cingulate cortex, and temporal cortex [24]. 
Imaging of activated microglia in the striatum could be used as a biomarker for 
detecting neuroinflammation in neurodegenerative parkinsonian disorders [25]. 
The resting microglia switches to an activated microglia phenotype in response 
to pathogen invasion or release of toxic or inflammatory mediators and thereby pro-
motes an inflammatory response [1]. Once activated, microglial cells produce a wide 
range of inflammatory mediators which serve to initiate an innate immune response 
or glial cell-propagated inflammation termed as neuroinflammation [26]. Also, the 
degenerating DA-neurons release many toxic factors that activate microglia and 
these degenerating neurons are vulnerable to inflammatory insult. Degenerating 
neurons will co-localize or attract an even larger population of microglia in the SN 
[27]. Collectively, these activated microglia and damaged neurons form a repetitive 
and vicious cycle that leads to chronic inflammation and continued extensive DA 
neurodegeneration over time, leading to the progression of PD [27]. These findings 
confirm neuroinflammation as a pivotal process in the progression of neurodegen-
erative disorders and the central role of microglia in this process [22]. Targeting 
neuroinflammatory pathways within microglia could be a significant step in the 
development of new therapeutics for neurodegenerative diseases, including PD.
4. Therapies targeting neurodegeneration/neuroinflammation in PD
Treatment for PD normally involves medications such as Levodopa to enhance 
the dopamine levels and deal with movement symptoms [28]. While none of our 
current treatments are able to stop the disease, medication and surgery can be 
helpful for managing the symptoms [29]. These treatments work well in patients 
initially, but they are also associated with unwanted side-effects and reduced 
efficacy over time [30]. On the other hand, many studies suggest that inflammatory 
mediators such as TNF, PGE2, NO, free radicals, and other immune mediators play 
role in the pathogenesis of PD and degeneration of dopamine-producing neurons 
and that targeting these mediators can be an effective treatment for PD. This opens 
up the potential of using anti-inflammatory drugs as an effective and long-term 
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erative disorders and the central role of microglia in this process [22]. Targeting 
neuroinflammatory pathways within microglia could be a significant step in the 
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Treatment for PD normally involves medications such as Levodopa to enhance 
the dopamine levels and deal with movement symptoms [28]. While none of our 
current treatments are able to stop the disease, medication and surgery can be 
helpful for managing the symptoms [29]. These treatments work well in patients 
initially, but they are also associated with unwanted side-effects and reduced 
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treatment in PD. These anti-inflammatory drugs can act by arresting the disease 
onset (primary prevention) or by interrupting or even reversing the disease 
progression (secondary prevention). Epidemiological and observational studies 
suggest that the use of anti-inflammatory drugs lower the risk of developing PD 
[31]. Observations which demonstrated that inflammation in SN plays a role in PD 
have led many investigators to initially consider the potential use of both steroidal 
and nonsteroidal anti-inflammatory drugs for the treatment of PD. Steroidal 
anti-inflammatory drugs (SAIDs), such as dexamethasone, have shown neuro-
protective effects in LPS-induced neurotoxicity in the SN in LPS models of PD 
[32]. Nonsteroidal anti-inflammatory drugs (NSAIDs) have also been used as 
analgesics and antipyretics to suppress the adverse effects of inflammation [33]. 
The neuroprotective effects of Ibuprofen have been studied in PD pathogenesis and 
these studies demonstrate the protective effect on dopaminergic neurons against 
glutamate toxicity in vitro [34, 35]. Previously, we have established several therapies 
targeting neuroinflammation and neurodegeneration in an animal model of PD and 
these therapies include D-morphinan-related compounds [36], anti-inflammatory 
cytokines such as TGF-β (transforming growth factor-beta) [37] and IL-10 [38, 39], 
IKK (inhibitor of kappa B (IκB) kinase) inhibitors [40], NADPH (nicotinamide 
adenine dinucleotide phosphate) oxidase inhibitors [41], and β2-AR (beta 2- 
adrenergic receptor) agonists [42, 43].
We have conducted a number of experiments using different classes of anti-
inflammatory compounds to determine their efficacy in preventing dopaminergic 
neurotoxicity by activated microglial cells both in vitro and in vivo. First, it was 
found that morphinan compounds and their stereoisomers (L-morphine and its D 
stereo enantiomers) can inhibit microglial activation and LPS- or MPP+-induced 
neurotoxicity in rat primary mesencephalic cultures. We and others observed that 
several dextrorotatory isomers of morphine compounds, including D-morphine, 
dextromethorphan, and sinomenine, showed neuroprotective effects against LPS 
and MPP+ (1-methyl-4-phenylpyridinium) which were mediated through the 
inhibition of microglial PHOX activity [36, 44, 45]. Furthermore, these studies 
also suggest that these morphinan compounds bind to the catalytic subunit of 
PHOX, inhibit its activity, and reduce the production of superoxide and other 
pro- inflammatory cytokines [44]. In another set of studies using a different 
anti-inflammatory approach, a specific inhibitor of IKK-β (IkappaB kinase-beta) 
protects dopaminergic neurons against LPS-induced neurotoxicity both in vitro and 
in vivo through inhibition of NF-κB activation, resulting in the decreased produc-
tion of ROS and inflammatory cytokines [40]. We have also developed therapies 
targeting neuroinflammation in PD models by using anti-inflammatory cytokines 
such as IL-10 and TGF-β1, and found that treatment with IL-10 on rat mesence-
phalic neuron-glia culture protects against LPS-induced neurotoxicity via suppres-
sion of pro-inflammatory mediators and superoxide production [38]. Similarly, 
the neuroprotective effect of TGFβ1 is primarily due to its ability to inhibit ERK 
phosphorylation, the serine phosphorylation on p47phox, and the production of ROS 
from microglia during activation by LPS [37].
5. Adrenergic receptors
One of the most potent and successful therapeutic treatments for inflammation-
mediated dopaminergic neurotoxicity is the use of long-acting agonists to the 
β2-AR. Adrenergic receptors (AR) are seven-transmembrane proteins that serve as 
adrenoreceptors for catecholamines such as norepinephrine and epinephrine on multiple 
cell types, and cells within the CNS that express AR include neurons, immune cells, and 
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astrocytes. Pharmacological classification of the adrenergic receptor was first introduced 
in 1948 and broadly classified as α and β adrenergic receptors [46] by Ahlquist. The 
classification was based on the order of potency and specificity of natural and synthetic 
agonist and blocking agents. The α-AR response corresponds to mainly excitatory 
response, while β-AR responses were correlated mainly with the inhibitory response. 
The α-AR response showed the order of potency: norepinephrine > epinephrine > 
isoproterenol and β-AR-mediated response exhibited order of potency: isoproterenol 
> epinephrine > norepinephrine [47, 48]. After the discovery of new drugs which have 
a high affinity to adrenergic receptors, these receptors were sub-classified. α-AR were 
subdivided into α1 and α2 adrenergic receptors [49]. Further studies subdivided β-AR 
into β1 and β2 which are normally present on immune cells, cardiac muscles, and airway 
smooth muscles, respectively [50]. A third β-AR, now called as β3-AR was identified on 
adipose tissues [51]. Tissue distribution, physiological effects, mechanism of action, and 
the major agonists/antagonists of ARs are summarized in Table 1. Pharmacological com-
pounds that serve as short, long, and ultra-long-acting agonists for these receptors have 
now been developed, and they are normally thought to stimulate adrenergic receptors by 
four different mechanisms: (1) by direct receptor binding, the most common mechanism 
where drugs activate peripheral adrenergic receptors via direct binding to receptor and 
mimic the actions of endogenous agonists (NE, epinephrine), (2) by ameliorating NE 
release, where drugs act on sympathetic nerve terminals and results into NE release, 
(3) by inhibition of NE reuptake, where these drugs can cause NE to accumulate within 
synaptic gaps at sympathetic nerve terminals, (4) by blockade of NE inactivation where 
drugs inhibit the activity of monoamine oxidase (MAO) which inhibits the activity of 
monoamines such as NE and dopamine [52].
6.  General properties of β2-adrenergic receptors: a G-protein-coupled 
receptor
6.1 Structure
The β2-ARs belong to a diverse superfamily of human cell surface seven trans-
membrane receptors for hormones and neurotransmitters called G-protein-coupled 
Table 1. 
Characteristics of adrenergic receptors.
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receptors (GPCRs). GPCRs are divided into six classes on basis of sequence 
homology: class A (Rhodopsin-like), class B (Secretin receptor family), class C 
(Metabotropic glutamate), class D (Fungal mating pheromone receptor), class E 
(Cyclic AMP receptor), and class F (Frizzled/smoothened) [53]. GPCRs are one of 
the most extensively studied proteins for the development of pharmaceutical drugs 
and target for approximately 50% of the marketed pharmaceutical drugs [54]. The 
adrenergic receptor family belongs to the rhodopsin-like subfamily, the largest class 
of the GPCR. The β2-AR is an intron-less gene is present on the long arm of chro-
mosome 5 (5q31) and encodes for 413 amino acid polypeptide of 46kD [55]. Similar 
to all GPCRs, β2-AR is composed of seven transmembrane spanning α-helices 
with an intracellular C-terminus and an extracellular N-terminus. The β2-AR was 
the first GPCR to be cloned [56] and the first GPCR structure to be solved [57]. 
The β2-AR has been studied extensively and also serves as a model system for 
investigating the regulation and signal transduction of GPCRs. The study of the 3D 
protein structure of this family of GPCRs took a giant leap forward when rhodopsin 
was first crystallized in 2000 and this crystalline structure has been used as an 
important template for modeling other GPCRs in this family [58]. The crystalline 
structure of human β2-AR was not solved until 2007, when a nonactive structure of 
β2-AR was identified [57]. Post-translational modifications such as glycosylation, 
pamitoylation, disulfide bond formation, and phosphorylation have now been 
found to affect receptor functions. Interestingly, β2-AR is glycosylated at amino 
acid 6, 15, and 187 which is important for the trafficking of the β2-AR from the 
endoplasmic reticulum to the plasma membrane [59]. Mutation in these sites also 
results in reduced expression of receptor on the cell membrane, suggesting a role 
for glycosylation in cell surface expression [60]. Conversely, the cysteine amino acid 
in the cytoplasmic tail at position 341 is palmitoylated, and is now found to be an 
important residue for the adequate coupling of the receptor to the Gs-protein [61]. 
Finally, β2-ARs have disulfide bonds which are essential for agonist binding and also 
for maintaining their tertiary structure [62].
6.2 Localization
Adrenergic receptors are widely distributed on human body organs and regulate 
physiologic functions such as bronchodilation [63], vasodilation, glycogenolysis in 
the liver, and relaxation of uterine and bladder muscles [64]. The human β2-AR are 
widely expressed not only on airway smooth muscles, but also on the wide variety 
of cells such as epithelial cells, endothelial cells, brain cells, and immune cells 
including mast cells, macrophages, adaptive immune cells, and eosinophils [65]. 
The expressions of β1- and β2-AR have also been found on microglial cells, suggest-
ing that microglia, the brain’s resident immune cell, is predominantly regulated by 
NE since NE is the predominant catecholamine in the CNS. Conversely, peripheral 
immune cells such as macrophages and T cells, which also express high levels of β1 
and β-2 AR, are thought to be regulated primarily by epinephrine [66].
6.3 β2-AR activation and signaling pathways in inflammation
Activation of adrenergic receptors could result into both pro- and anti- 
inflammatory actions, depending on certain parameters such as the type of cell, 
duration of ligand exposure to the receptor, and type of the adrenergic receptor 
[67]. It is the diversity of the β2-AR that leads to the complexity of signaling mecha-
nisms and to this duality of function. Activation of β2-AR by receptor agonists initi-
ate intracellular signaling pathways that function either via G-proteins or through 
β-arrestins. Like other GPCR, β2-AR can activate either canonical (traditional) 
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or noncanonical (nontraditional) signal transduction pathway. In the canonical 
pathway, similar to a typical GPCR the β2-AR signals via a heterotrimeric G-protein 
complex, and when the receptor is coupled to inactive GDP-bound G-protein, it 
appears to have high affinity to the agonist or ligand. After ligand binding, the 
transmembrane domains of the receptor undergo conformational change with the 
exchange of GDP to GTP. Further, this conformational change reduces the affinity 
of the ligand to its receptor, increasing the possibility of retraction of ligand from 
the receptor, thereby preventing the over-activation of G-protein. This provides 
evidence that β2-AR appear to oscillate between an active and inactive form under 
normal conditions. After the exchange of GDP to GTP, the Gα-subunit dissoci-
ates from Gβγ-subunit which remains associated with plasma membrane and the 
Gα-subunit activates effector proteins. The downstream signaling of this process 
normally results in the production of intracellular second messengers which further 
activates the cAMP-PKA-mediated intracellular signaling pathway. The activated 
β2-AR binds with the α-subunit of the G-protein together with a guanosine triphos-
phate (GTP) molecule. Further, the receptor coupled with adenylate cyclase (AC) 
which catalyzes the conversion of ATP into cAMP (a second messenger for β2-AR) 
by hydrolysis of GTP into GDP. The cAMP activates and regulates protein kinase A 
(PKA) which further mediates the transcription of genes and degradation of cAMP 
by phosphodiesterase (PDE) leading to termination of signaling [68].
Earlier it was determined that β2-AR exhibits their inhibitory signals in immune 
cells via the canonical (PKA) signaling pathway. It has now been found that GPCR 
can also signal through a noncanonical pathway in addition to their classical 
signaling pathway [69]. Activation through the noncanonical signaling pathway is 
cell type dependent and G-protein independent, but rather the G-protein-coupled 
receptor kinases (GRKs) and β-arrestins are involved in activation of this nonca-
nonical signaling pathway. Various types of GRKs phosphorylate specifically serine 
and threonine at C-terminal of the β2-AR which further determines whether recep-
tors undergo desensitization or initiate noncanonical signaling [70]. For example, 
phosphorylation of receptor by GRK5/6 initiates β-arrestin-mediated noncanonical 
signaling, while phosphorylation by GRK2 leads to β-arrestin-mediated desensitiza-
tion of the receptor [71]. During noncanonical signaling, β-arrestin2 couples β2-AR 
to MAPK signaling pathways which induces activation of transcription factors and 
allows their nuclear translocation. Activation of β2-AR with high agonist concentra-
tion can lead to sustained activation of ERK1/2 via β-arrestin2. This explains why 
β2-AR activation can either enhance or suppress the proliferation of immune cells 
and cytokine production particularly at a high concentration of agonists [67, 72]. 
Studies suggest that during inflammatory conditions immune cells can switch from 
canonical to the noncanonical pathway [67, 68]. Engagement of β2-AR receptors 
by agonists can result in immunomodulatory actions. Depending on the type of 
immune stimuli and timing of β2-AR activation relative to immune activation, 
β2-AR stimulation can positively or negatively regulate the response of immune 
activator [67, 73]. The initial data obtained in animal models of dopaminergic 
neurotoxicity suggests that the primary immunomodulatory mechanism of β2-AR 
activation that regulates CNS inflammation in microglial cells occurs through the 
noncanonical β-arrestin2 pathway of activation.
7. β2-agonists
β-agonists are a group of pharmaceutical compounds or sympathomimetic 
drugs that mimic the effects of endogenous catecholamines such as epinephrine, 
norepinephrine, and dopamine. These drugs do not comprise a similar structure to 
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receptors (GPCRs). GPCRs are divided into six classes on basis of sequence 
homology: class A (Rhodopsin-like), class B (Secretin receptor family), class C 
(Metabotropic glutamate), class D (Fungal mating pheromone receptor), class E 
(Cyclic AMP receptor), and class F (Frizzled/smoothened) [53]. GPCRs are one of 
the most extensively studied proteins for the development of pharmaceutical drugs 
and target for approximately 50% of the marketed pharmaceutical drugs [54]. The 
adrenergic receptor family belongs to the rhodopsin-like subfamily, the largest class 
of the GPCR. The β2-AR is an intron-less gene is present on the long arm of chro-
mosome 5 (5q31) and encodes for 413 amino acid polypeptide of 46kD [55]. Similar 
to all GPCRs, β2-AR is composed of seven transmembrane spanning α-helices 
with an intracellular C-terminus and an extracellular N-terminus. The β2-AR was 
the first GPCR to be cloned [56] and the first GPCR structure to be solved [57]. 
The β2-AR has been studied extensively and also serves as a model system for 
investigating the regulation and signal transduction of GPCRs. The study of the 3D 
protein structure of this family of GPCRs took a giant leap forward when rhodopsin 
was first crystallized in 2000 and this crystalline structure has been used as an 
important template for modeling other GPCRs in this family [58]. The crystalline 
structure of human β2-AR was not solved until 2007, when a nonactive structure of 
β2-AR was identified [57]. Post-translational modifications such as glycosylation, 
pamitoylation, disulfide bond formation, and phosphorylation have now been 
found to affect receptor functions. Interestingly, β2-AR is glycosylated at amino 
acid 6, 15, and 187 which is important for the trafficking of the β2-AR from the 
endoplasmic reticulum to the plasma membrane [59]. Mutation in these sites also 
results in reduced expression of receptor on the cell membrane, suggesting a role 
for glycosylation in cell surface expression [60]. Conversely, the cysteine amino acid 
in the cytoplasmic tail at position 341 is palmitoylated, and is now found to be an 
important residue for the adequate coupling of the receptor to the Gs-protein [61]. 
Finally, β2-ARs have disulfide bonds which are essential for agonist binding and also 
for maintaining their tertiary structure [62].
6.2 Localization
Adrenergic receptors are widely distributed on human body organs and regulate 
physiologic functions such as bronchodilation [63], vasodilation, glycogenolysis in 
the liver, and relaxation of uterine and bladder muscles [64]. The human β2-AR are 
widely expressed not only on airway smooth muscles, but also on the wide variety 
of cells such as epithelial cells, endothelial cells, brain cells, and immune cells 
including mast cells, macrophages, adaptive immune cells, and eosinophils [65]. 
The expressions of β1- and β2-AR have also been found on microglial cells, suggest-
ing that microglia, the brain’s resident immune cell, is predominantly regulated by 
NE since NE is the predominant catecholamine in the CNS. Conversely, peripheral 
immune cells such as macrophages and T cells, which also express high levels of β1 
and β-2 AR, are thought to be regulated primarily by epinephrine [66].
6.3 β2-AR activation and signaling pathways in inflammation
Activation of adrenergic receptors could result into both pro- and anti- 
inflammatory actions, depending on certain parameters such as the type of cell, 
duration of ligand exposure to the receptor, and type of the adrenergic receptor 
[67]. It is the diversity of the β2-AR that leads to the complexity of signaling mecha-
nisms and to this duality of function. Activation of β2-AR by receptor agonists initi-
ate intracellular signaling pathways that function either via G-proteins or through 
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or noncanonical (nontraditional) signal transduction pathway. In the canonical 
pathway, similar to a typical GPCR the β2-AR signals via a heterotrimeric G-protein 
complex, and when the receptor is coupled to inactive GDP-bound G-protein, it 
appears to have high affinity to the agonist or ligand. After ligand binding, the 
transmembrane domains of the receptor undergo conformational change with the 
exchange of GDP to GTP. Further, this conformational change reduces the affinity 
of the ligand to its receptor, increasing the possibility of retraction of ligand from 
the receptor, thereby preventing the over-activation of G-protein. This provides 
evidence that β2-AR appear to oscillate between an active and inactive form under 
normal conditions. After the exchange of GDP to GTP, the Gα-subunit dissoci-
ates from Gβγ-subunit which remains associated with plasma membrane and the 
Gα-subunit activates effector proteins. The downstream signaling of this process 
normally results in the production of intracellular second messengers which further 
activates the cAMP-PKA-mediated intracellular signaling pathway. The activated 
β2-AR binds with the α-subunit of the G-protein together with a guanosine triphos-
phate (GTP) molecule. Further, the receptor coupled with adenylate cyclase (AC) 
which catalyzes the conversion of ATP into cAMP (a second messenger for β2-AR) 
by hydrolysis of GTP into GDP. The cAMP activates and regulates protein kinase A 
(PKA) which further mediates the transcription of genes and degradation of cAMP 
by phosphodiesterase (PDE) leading to termination of signaling [68].
Earlier it was determined that β2-AR exhibits their inhibitory signals in immune 
cells via the canonical (PKA) signaling pathway. It has now been found that GPCR 
can also signal through a noncanonical pathway in addition to their classical 
signaling pathway [69]. Activation through the noncanonical signaling pathway is 
cell type dependent and G-protein independent, but rather the G-protein-coupled 
receptor kinases (GRKs) and β-arrestins are involved in activation of this nonca-
nonical signaling pathway. Various types of GRKs phosphorylate specifically serine 
and threonine at C-terminal of the β2-AR which further determines whether recep-
tors undergo desensitization or initiate noncanonical signaling [70]. For example, 
phosphorylation of receptor by GRK5/6 initiates β-arrestin-mediated noncanonical 
signaling, while phosphorylation by GRK2 leads to β-arrestin-mediated desensitiza-
tion of the receptor [71]. During noncanonical signaling, β-arrestin2 couples β2-AR 
to MAPK signaling pathways which induces activation of transcription factors and 
allows their nuclear translocation. Activation of β2-AR with high agonist concentra-
tion can lead to sustained activation of ERK1/2 via β-arrestin2. This explains why 
β2-AR activation can either enhance or suppress the proliferation of immune cells 
and cytokine production particularly at a high concentration of agonists [67, 72]. 
Studies suggest that during inflammatory conditions immune cells can switch from 
canonical to the noncanonical pathway [67, 68]. Engagement of β2-AR receptors 
by agonists can result in immunomodulatory actions. Depending on the type of 
immune stimuli and timing of β2-AR activation relative to immune activation, 
β2-AR stimulation can positively or negatively regulate the response of immune 
activator [67, 73]. The initial data obtained in animal models of dopaminergic 
neurotoxicity suggests that the primary immunomodulatory mechanism of β2-AR 
activation that regulates CNS inflammation in microglial cells occurs through the 
noncanonical β-arrestin2 pathway of activation.
7. β2-agonists
β-agonists are a group of pharmaceutical compounds or sympathomimetic 
drugs that mimic the effects of endogenous catecholamines such as epinephrine, 
norepinephrine, and dopamine. These drugs do not comprise a similar structure to 
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catecholamines but still directly or indirectly activate the β2-adrenergic receptor. 
The first β-agonist was used around 5000 years ago in Chinese medicine where an 
ephedrine containing plant, Ma-huang, was used to treat respiratory problems [74]. 
Further research in the twentieth century has led to increased use of β-agonists for 
the treatment of respiratory diseases. The first β2-AR selective agonist, Salbutamol 
was synthesized by Glaxo in 1968 [75]. Later, the same team at Glaxo modified 
Salbutamol into Salmeterol with long-lasting effects and reduced side effects. 
Recently, they have synthesized β2-agonists with ultra-long-lasting effects such as 
Indacaterol [76]. After successful trials, these β2-agonists were approved by the US 
Food and Drug Administration (FDA) for the treatment of respiratory diseases such 
as asthma and chronic obstructive pulmonary disease (COPD). Since 1968, a num-
ber of companies have labored to develop β2-AR agonists, and some have now been 
commercialized for use in the treatment of COPD. A list of some of these agonists is 
given below and in Table 1.
7.1 Classification of β2-agonists
A pharmacogenetic study of β2-agonists has summarized the relationship 
between polymorphisms in the β2-adrenoreceptor (ADRB2) gene and the effects 
of select β2-agonists [77]. Two hypotheses aim to account for the differences in 
functioning and in vivo half-lives of these compounds: exosite/exoreceptor or 
plasmalemma diffusion microkinetics. Briefly, the exosite hypothesis focuses 
on the ability of the side-chain of these compounds to interact with a distinct 
site on the receptor such that it allows the active component to “swing back-
and-forth” to activate the receptor. The plasmalemma diffusion microkinetic 
hypothesis suggests that high concentrations of agonists are achieved in close 
proximity to the receptor and allows for a longer duration of action [78]. Both of 
these hypotheses require further investigation and need to be studied within the 
CNS. Depending upon their mechanism and duration of action, all β2-agonists 
are grouped into three major classes: short-acting, long-acting, and ultra-long-
acting β2-agonists.
7.1.1 Short-acting β-agonists (SABA)
These drugs are mostly hydrophilic in nature, access the active site of β-AR 
directly from the aqueous extracellular area and show the fast onset of action [79]. 
These SABAs bind to the receptor for short time; therefore, their duration of 
action is short. Some of the more common SABAs include Salbutamol (Ventolin), 
Albuterol (AccuNeb), Pirbuterol (Maxair), and Levalbuterol (Xopenex).
7.1.2 Long-acting β-agonists (LABA)
These drugs are a frontline treatment for COPD, and usually prescribed alone 
or in combination with inhaled corticosteroids. LABAs are lipophilic in nature and 
taken up by cell membrane as a reservoir, progressively seep out and interact with 
the active site of the receptor [79]. They diffuse in the plasma membrane, where 
they interact with the active site of the β2-AR which allows for the close proximity 
with the receptor and longer duration of action. The onset of action of these drugs 
is slower as compared to SABAs, but the duration of action is prolonged thereby, 
called as LABAs. The duration of action is also dependent on the concentration of 
the agonist. Salmeterol, Salmeterol with an inhaled corticosteroid, Formoterol, and 
Formoterol with an inhaled corticosteroid are commercially available LABAs and 
used in medication for asthma and COPD [80].
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7.1.3 Ultra-long-acting β-agonists
These agonists are also lipophilic in nature and onset of action is similar to 
LABAs, but the duration of action lasts longer than LABAs. Vilanterol with an 
inhaled corticosteroid and Indacaterol are ultra-LABAs, approved by FDA for the 
treatment of COPD [81].
8. β2-adrenergic receptors agonists in neuroprotection
The majority of adrenergic neurons are present in brainstem locus coeruleus (LC) 
nuclei, which is a predominant site for the production of norepinephrine (NE) in the 
brain. LC neurons play a key role in the regulation of cognitive behavior such as atten-
tion, mood, and arousal [82]. These neurons also play role in the development of the 
brain, mainly the neocortex [83]. The degeneration of LC-neurons has been identified in 
patients with PD and AD [84]. Also, the classical “monoamine hypothesis of depression” 
says that the deficiency of NE is a culprit for the cognitive impairment [85]. NE/noradren-
aline, the primary neurotransmitter released by the LC neurons targets the adrenergic 
receptors present on the microglia and astrocytes in the brain [86]. NE-activated ARs on 
glial cells stimulate the second messenger system and maintain the homeostasis in the 
brain. Activation of AR on glial cells elicits anti-inflammatory actions, inhibits neuroin-
flammation, and thereby limits the degeneration of neurons [87]. Moreover, drugs that 
stimulate the release of NE/NA have potential to reduced inflammation and amyloid 
pathology in a mouse model of AD [88]. According to Braak’s hypothesis, early stage of 
progression starts in LC before it spreads to SN [89]. Overall, these and many other stud-
ies suggest the role of the adrenergic signaling in neurodegeneration. Therefore, enhanc-
ing NE/NA signaling, transplanting noradrenergic neurons, or use of drugs that mimic 
the activity of NA/NE on glial cells have great potential to reverse or halt the progressive 
degeneration of neurons [90]. The endogenous agonist/ligand for β2-AR is norepi-
nephrine which acts as a neurotrophic factor and can influence protein/DNA synthesis 
in developing adult brain [91, 92]. NE protects cholinergic and dopaminergic cultured 
neurons against oxidative stress and catechol moiety of NE plays role in neuroprotection 
[93, 94]. It suggests that a compound containing catechol moiety, such as β-agonists, can 
mimic the neuroprotective effects of NE. Treatment with NE stimulates the synthesis of 
BDNF in astrocytes and neuron in vitro and in vivo [95, 96] and these neuroprotective 
effects were reversed by the antagonist of α1, β1, and β2-AR [97].
The use of β2-agonists as an adjunct therapy to L-DOPA in PD was first described in 
1994 [98]. Chai et al. showed that the β2-AR activation enhances hippocampal neu-
rogenesis, ameliorates memory deficits, and increases dendritic branching and spine 
density in a mouse model of Alzheimer’s disease [99]. Recently, Mittal et al. have found 
that β2-AR activation regulates the gene expression of α-synuclein in various animal 
and in vitro models of PD. Salbutamol, a blood-brain-barrier-permeable β2-agonist, 
reduces expression of SNCA gene via histone-3-lysine-27 acetylation of its promoter 
and enhancer. They also analyzed the pharmacological history of 4 million Norwegians 
over 11 years and found that Salbutamol was also associated with reduced risk of 
developing PD [100]. In a mouse model of Down syndrome, Formoterol, a long-acting 
β2-AR agonist, causes significant improvement in synaptic density and cognitive func-
tions [101]. Salmeterol (Sal) is an inhaled long-acting highly selective β2-AR agonist 
which is currently being used as the active ingredient in Advair@ as a bronchodilator. 
Our previous studies and others have shown that Salmeterol has anti-inflammatory and 
DA-neuroprotective activities, even at very low doses. Pre-treatment with Salmeterol 
protects DA neurons against LPS- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP)-induced toxicity in both in vitro and in vivo animal models of PD [42, 102]. The 
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catecholamines but still directly or indirectly activate the β2-adrenergic receptor. 
The first β-agonist was used around 5000 years ago in Chinese medicine where an 
ephedrine containing plant, Ma-huang, was used to treat respiratory problems [74]. 
Further research in the twentieth century has led to increased use of β-agonists for 
the treatment of respiratory diseases. The first β2-AR selective agonist, Salbutamol 
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Salbutamol into Salmeterol with long-lasting effects and reduced side effects. 
Recently, they have synthesized β2-agonists with ultra-long-lasting effects such as 
Indacaterol [76]. After successful trials, these β2-agonists were approved by the US 
Food and Drug Administration (FDA) for the treatment of respiratory diseases such 
as asthma and chronic obstructive pulmonary disease (COPD). Since 1968, a num-
ber of companies have labored to develop β2-AR agonists, and some have now been 
commercialized for use in the treatment of COPD. A list of some of these agonists is 
given below and in Table 1.
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A pharmacogenetic study of β2-agonists has summarized the relationship 
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site on the receptor such that it allows the active component to “swing back-
and-forth” to activate the receptor. The plasmalemma diffusion microkinetic 
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directly from the aqueous extracellular area and show the fast onset of action [79]. 
These SABAs bind to the receptor for short time; therefore, their duration of 
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7.1.2 Long-acting β-agonists (LABA)
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taken up by cell membrane as a reservoir, progressively seep out and interact with 
the active site of the receptor [79]. They diffuse in the plasma membrane, where 
they interact with the active site of the β2-AR which allows for the close proximity 
with the receptor and longer duration of action. The onset of action of these drugs 
is slower as compared to SABAs, but the duration of action is prolonged thereby, 
called as LABAs. The duration of action is also dependent on the concentration of 
the agonist. Salmeterol, Salmeterol with an inhaled corticosteroid, Formoterol, and 
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used in medication for asthma and COPD [80].
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7.1.3 Ultra-long-acting β-agonists
These agonists are also lipophilic in nature and onset of action is similar to 
LABAs, but the duration of action lasts longer than LABAs. Vilanterol with an 
inhaled corticosteroid and Indacaterol are ultra-LABAs, approved by FDA for the 
treatment of COPD [81].
8. β2-adrenergic receptors agonists in neuroprotection
The majority of adrenergic neurons are present in brainstem locus coeruleus (LC) 
nuclei, which is a predominant site for the production of norepinephrine (NE) in the 
brain. LC neurons play a key role in the regulation of cognitive behavior such as atten-
tion, mood, and arousal [82]. These neurons also play role in the development of the 
brain, mainly the neocortex [83]. The degeneration of LC-neurons has been identified in 
patients with PD and AD [84]. Also, the classical “monoamine hypothesis of depression” 
says that the deficiency of NE is a culprit for the cognitive impairment [85]. NE/noradren-
aline, the primary neurotransmitter released by the LC neurons targets the adrenergic 
receptors present on the microglia and astrocytes in the brain [86]. NE-activated ARs on 
glial cells stimulate the second messenger system and maintain the homeostasis in the 
brain. Activation of AR on glial cells elicits anti-inflammatory actions, inhibits neuroin-
flammation, and thereby limits the degeneration of neurons [87]. Moreover, drugs that 
stimulate the release of NE/NA have potential to reduced inflammation and amyloid 
pathology in a mouse model of AD [88]. According to Braak’s hypothesis, early stage of 
progression starts in LC before it spreads to SN [89]. Overall, these and many other stud-
ies suggest the role of the adrenergic signaling in neurodegeneration. Therefore, enhanc-
ing NE/NA signaling, transplanting noradrenergic neurons, or use of drugs that mimic 
the activity of NA/NE on glial cells have great potential to reverse or halt the progressive 
degeneration of neurons [90]. The endogenous agonist/ligand for β2-AR is norepi-
nephrine which acts as a neurotrophic factor and can influence protein/DNA synthesis 
in developing adult brain [91, 92]. NE protects cholinergic and dopaminergic cultured 
neurons against oxidative stress and catechol moiety of NE plays role in neuroprotection 
[93, 94]. It suggests that a compound containing catechol moiety, such as β-agonists, can 
mimic the neuroprotective effects of NE. Treatment with NE stimulates the synthesis of 
BDNF in astrocytes and neuron in vitro and in vivo [95, 96] and these neuroprotective 
effects were reversed by the antagonist of α1, β1, and β2-AR [97].
The use of β2-agonists as an adjunct therapy to L-DOPA in PD was first described in 
1994 [98]. Chai et al. showed that the β2-AR activation enhances hippocampal neu-
rogenesis, ameliorates memory deficits, and increases dendritic branching and spine 
density in a mouse model of Alzheimer’s disease [99]. Recently, Mittal et al. have found 
that β2-AR activation regulates the gene expression of α-synuclein in various animal 
and in vitro models of PD. Salbutamol, a blood-brain-barrier-permeable β2-agonist, 
reduces expression of SNCA gene via histone-3-lysine-27 acetylation of its promoter 
and enhancer. They also analyzed the pharmacological history of 4 million Norwegians 
over 11 years and found that Salbutamol was also associated with reduced risk of 
developing PD [100]. In a mouse model of Down syndrome, Formoterol, a long-acting 
β2-AR agonist, causes significant improvement in synaptic density and cognitive func-
tions [101]. Salmeterol (Sal) is an inhaled long-acting highly selective β2-AR agonist 
which is currently being used as the active ingredient in Advair@ as a bronchodilator. 
Our previous studies and others have shown that Salmeterol has anti-inflammatory and 
DA-neuroprotective activities, even at very low doses. Pre-treatment with Salmeterol 
protects DA neurons against LPS- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP)-induced toxicity in both in vitro and in vivo animal models of PD [42, 102]. The 
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mechanism how Salmeterol regulates the activation of microglia is described in  
Figure 1. Collectively, these studies suggest that β2-AR agonists not only protect neu-
rons against degeneration, but also have anti-inflammatory effects, and therefore, hold 
significant promise for the treatments of a wide variety of neurodegenerative condi-
tions including PD [43]. The clinical efficacy of β2-AR agonists have been examined in 
various neurological disorders and few of them are summarized in Table 2.
Disease Condition Design Doses Drug References
Spinal Cord Injury Randomized 
controlled
4mg twice/day 




Alzheimer’s Disease Randomized 
controlled
20mg/2ml for 12 
months
Formoterol [130]
Multiple Sclerosis Blinded 
controlled
4mg/day Albuterol [131]






Memory and Cognition Randomized 
controlled
4mg, single oral 
administration
Salbutamol [133]
SMA Uncontrolled 3-8mg/day for 6 
months
Albuterol [134]
ALS Uncontrolled 60ug/day for 6 
months
Clenbuterol [135]




SMA: Spinal Muscular Atrophy, SBMA: Spinal and Bulbar Muscular Atrophy, ALS: Amyotrophic Lateral Sclerosis.
Table 2. 
Clinical trials using β2-agonist in neurological conditions.
Figure 1. 
Schematic of microglia-mediated neurotoxicity and inhibitory effects of Salmeterol on microglial activation.
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9. β2-adrenergic receptors and neuroinflammation
Extensive previous investigations into the etiology of PD demonstrate a central 
role for the inflammatory microglial cell in the progression of PD. Thus, targeting 
neuroinflammation mediated by microglia may serve as a potential therapeutic 
benefit in the treatment of PD. Since traditional treatment for PD is aimed only at 
controlling the disease symptoms, the search for more effective neuroprotective 
therapies which target the cause of the disease is now receiving significant atten-
tion. Studies targeting neuroinflammation are aimed to promote the development 
of a novel therapeutic approach and aid in the drug discovery for neurodegenerative 
conditions such as PD.
One such anti-inflammatory approach that has been found to be effective in 
protection against dopaminergic neurodegeneration is accomplished by natural 
and therapeutic compounds that activate the β2-AR. Brain cells including neurons, 
microglia, and astrocytes as well as immune cells express a high density of β2-AR on 
their surface [66, 103]. Catecholamines such as epinephrine (adrenaline), norepi-
nephrine (noradrenaline), and dopamine are the most abundant catecholamines 
found in the nervous system. As evidenced by many unrelated studies, catechol-
amines can modulate the immune response [87, 104]. Further studies have found 
that the endogenous agonist of β2-AR, norepinephrine (NE), controls microglial 
motility and functions during pathogenic conditions [105]. NE also protects cortical 
neurons against microglia-mediated inflammation, while decreased levels of NE 
enhance microglial activation [106]. One study showed that β2-AR negatively 
regulates NF-κB activation and stabilizes the NF-κB/IκBα complex via β-arrestin 
2 in LPS activated murine macrophages [107]. Interestingly, activation of β2-AR in 
astrocytes modulates TNF-α-induced inflammatory gene expression in vitro and 
in vivo. In addition, an in vivo study demonstrated increased expression of β2-AR 
in glial cells in response to neuronal injury. This suggests that β2-AR may provide 
a therapeutic target for regulation of glial cell functioning and the inflammatory 
response in the brain [108]. Activation of β2-AR on astrocytes stimulates the release 
of trophic factors such as BDNF, bFGF, NGF-1, and TGF-β1 via canonical signaling, 
showing anti-apoptotic and neuroprotective effects in animal models of cerebral 
ischemia and excitotoxicity [109, 110]. It has also been shown that noradrenaline 
acting on β2-AR enhances the expression of anti-inflammatory and neurotrophic 
cytokine IL-10 in the brain. This suggests an endogenous ligand of β2-AR is neu-
roprotective during inflammatory conditions in CNS disease pathology [108, 111]. 
Both canonical and noncanonical signaling of β2-AR can selectively regulate 
the adaptive immune response [67], since β2-AR are expressed by naïve CD4+ T 
(T-helper (Th0)) and Th1 cells but absent on Th2 cells [112, 113]. Naïve CD4+ T-cell 
treated with a β2-AR agonist or NE suppresses the production of interferon (IFN)-γ 
and IL-2 and affects their differentiation [114]. Collectively, these studies and 
several others suggest the role of β2-AR in the regulation of immune response.
10.  Molecular mechanism of inflammation in PD or molecular mediators 
of inflammation in PD
10.1 Effect of β2-AR agonists on NF-κB pathway
We have characterized and examined the effects of β2-AR agonists including 
Salbutamol, Salmeterol, Indacaterol, and Vilanterol on neuroinflammation in 
models of PD in vitro and in vivo. However, the short-acting agonists were neuropro-
tective and able to reduce inflammation in vitro at higher doses, but the long-acting 
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mechanism how Salmeterol regulates the activation of microglia is described in  
Figure 1. Collectively, these studies suggest that β2-AR agonists not only protect neu-
rons against degeneration, but also have anti-inflammatory effects, and therefore, hold 
significant promise for the treatments of a wide variety of neurodegenerative condi-
tions including PD [43]. The clinical efficacy of β2-AR agonists have been examined in 
various neurological disorders and few of them are summarized in Table 2.
Disease Condition Design Doses Drug References
Spinal Cord Injury Randomized 
controlled
4mg twice/day 




Alzheimer’s Disease Randomized 
controlled
20mg/2ml for 12 
months
Formoterol [130]
Multiple Sclerosis Blinded 
controlled
4mg/day Albuterol [131]






Memory and Cognition Randomized 
controlled
4mg, single oral 
administration
Salbutamol [133]
SMA Uncontrolled 3-8mg/day for 6 
months
Albuterol [134]
ALS Uncontrolled 60ug/day for 6 
months
Clenbuterol [135]




SMA: Spinal Muscular Atrophy, SBMA: Spinal and Bulbar Muscular Atrophy, ALS: Amyotrophic Lateral Sclerosis.
Table 2. 
Clinical trials using β2-agonist in neurological conditions.
Figure 1. 
Schematic of microglia-mediated neurotoxicity and inhibitory effects of Salmeterol on microglial activation.
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9. β2-adrenergic receptors and neuroinflammation
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agonist showed beneficial effects at low concentration (10−9 M) in neurotoxicity 
and inflammatory models of PD. Salmeterol, a β2-AR agonist, can effectively serve 
as a therapeutic treatment for PD by inhibiting microglia-mediated inflamma-
tory responses in vivo. We have found that Salmeterol functions to inhibit innate 
pro-inflammatory response in both murine macrophages and microglia through its 
inhibition of the NF-κB signaling pathways [42]. We have also investigated whether 
Salmeterol is specific to neuroinflammation in PD or if it can be used as a universal 
anti-inflammatory drug against other chronic inflammatory diseases. To test this, 
we used murine macrophages stimulated with LPS from Porphyromonas gingivalis 
(PgLPS), an oral pathogen as an in vitro model for the periodontal disease. We have 
found that Salmeterol shows similar anti-inflammatory effects on PgLPS-stimulated 
macrophages [115]. Additionally, Feng et al. have also shown neuroprotective effects 
of β-arrestin2 via endogenous opioid arrest in inflammatory microglial cells [116].
10.2 Effect of β2-AR agonists on MAPK pathway
The agonist-activated β2-AR stimulates MAPK signaling pathway via noncanonical 
and G-protein independent pathway. Agonist-activated β2-AR reduces phosphoryla-
tion of ERK1/2 and p38 MAPK in macrophages stimulated with LPS. In contrast, 
β2-AR activation stimulates MAPK signaling and TNF-α, IL-12, and NO production 
in murine macrophages treated with PMA (phorbol 12-myristate-13-acetate) [73]. 
Similarly, our previous studies have shown that activation of β2-AR with the high con-
centration of agonist (up to 10−5 M) leads to sustained phosphorylation of ERK1/2 and 
enhanced production inflammatory mediators in murine microglia and macrophages 
[117]. High-dose treatment of β2-AR agonists on mixed neuroglia culture enhances 
neurotoxicity via NADPH oxidase activity in the ERK-dependent manner [118]. Like 
others, we have found that the low-doses of the β2-AR agonist Salmeterol reduces the 
MAPK activity, NF-κB activation and production of TNF-α in LPS-activated primary 
microglia [42]. We have also found that low-dose Salmeterol inhibits the phosphoryla-
tion of TAK1 (TGF-β-activated kinase1) which is an upstream regulator of NF-κB 
signaling in LPS-stimulated microglia. We have also found that Salmeterol increases 
the expression of β-arrestin2 and enhances the interaction between β-arrestin2 and 
TAB1 (TAK1-binding protein), reduced TAK1/TAB1 mediated activation of NFκB and 
expression of pro-inflammatory genes. Furthermore, silencing of β-arrestin2 abro-
gates the anti-inflammatory effects of Salmeterol in LPS-stimulated BV2 cells [119]. 
These studies suggest that the anti-inflammatory effects of Salmeterol work through 
the inhibition of pro-inflammatory pathways in microglial cells.
10.3 The β-arrestin-mediated biased effects of β2-AR agonist
Previous findings show that high dose Salmeterol enhances the expression of 
IL-1β and IL-6 mRNA and protein in unstimulated human monocytes and murine 
macrophages. These effects were β-arrestin2-dependent but PKA and NF-κB 
independent, while treatment with ERK1/2 and p38 MAPK inhibitor could reverse 
this effect [117]. This finding and several others suggest Salmeterol or other long-
acting agonist have β-arrestin “biased” signaling of β2-AR. These agonists activate 
receptors via β-arrestin signaling with a much greater extent than their effect on 
G-protein-dependent signaling [120]. Our studies suggest that a very low concen-
tration of Salmeterol does not enhance cAMP signaling and its downstream media-
tors, while it activates the β-arrestin2-mediated signaling events [42]. β-arrestin2 
has been shown as a novel regulator of IκB stability via the direct interaction of 
β-arrestin2 and IκB in HEK293 cells [121]. In addition, β-arrestin2 negatively regu-
lates the activation of NF-κB via direct binding with IκBα [122]. One study showed 
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that overexpression of β-arrestin2 significantly reduces L-DOPA-induced dyski-
nesia in animal models of PD [123]. Collectively, these studies suggest that β2-AR 
agonists can be used therapeutically not only to inhibit chronic inflammation and 
progressive degeneration of neurons, but also to treat some of the most debilitating 
neurologic symptoms in PD.
10.4 cAMP/PKA/CREB pathway induced by β2-AR
After binding with an agonist or endogenous ligand, β2-AR normally activates 
the classical cAMP-dependent signaling pathway. The downstream effect of the 
cAMP/PKA pathway is the phosphorylation and nuclear translocation of the CREB 
transcription factor which further enhances the expression of cAMP-inducible 
genes [79]. Activation of CREB via this pathway regulates the synthesis of proteins 
which are mandatory for neuronal homeostasis [124]. The classical signaling of 
β2-AR also increases the activity of PGC-1α (Peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha), which is a key regulator of mitochondrial 
biogenesis and ROS metabolism [125]. Activation of β2-AR also elevated the release 
of neurotrophic factors via cAMP/PKA/CREB pathway and provides neuroprotec-
tive benefits against degeneration [126]. An endogenous agonist of β2-AR (NE) 
affects immune cell functions, production of cytokines, and antibody secretion 
[112]. β2-AR agonists have anti-inflammatory activity and inhibit release of pro-
inflammatory mediators via cAMP/PKA/CREB pathway and also by alternate 
cAMP-dependent pathway (cAMP/Epac1/2) [42, 127, 128]. We have also found that 
pro-inflammatory effects of high-dose of Salmeterol are through cAMP/Epac path-
way, while the anti-inflammatory effects of low-dose of Salmeterol are independent 
on cAMP and Epac activation [42, 118].
11. From bench to bedside: challenges in translation to the clinic
The β2-AR agonists discussed above are FDA-approved for the treatment of 
respiratory diseases such as asthma and COPD, but none of these β2-AR agonists 
are specifically developed for PD. Although, Mittal et al. have found in a Norwegian 
population that using Salbutamol, a SABA, lower the risk of developing PD whereas 
the use of Propranolol, a β2-AR antagonist (commonly used to treat hypertension 
and certain other forms of heart disease) was associated with increased risk of PD 
[100]. Furthermore, this risk of developing PD was dependent on the duration of 
Salbutamol intake in those patients. In the patient population who used Salbutamol 
for at least 6 months, it was expected that 43 would develop PD, but only 23 patients 
were ultimately diagnosed with the disease (rate ratio 0.66). On the other hand, in 
the cohort who used Salbutamol for 2 months or less, there was no decreased risk 
of developing PD in this population [100]. In contrast, patients on Propranolol 
(which is also used as therapeutic for tremors in PD) for at least 1 year showed a 
significantly increased risk of developing PD compared to patients not on propranolol 
(rate ratio 2.2). Therefore, it is clear that patients on long-term Salbutamol (a β2-AR 
agonist) had significantly decreased the risk of developing PD, while patients on 
long-term propranolol (a β2-AR antagonist) therapy had significantly higher rates 
of PD, suggesting that β2-AR inhibition is a highly significant risk factor in develop-
ing PD. When we compared the effectiveness of Salbutamol to Salmeterol (a more 
lipophilic drug) in animal models of PD, Salmeterol was much more effective both in 
vitro and in vivo in dopaminergic neuroprotection [42]. More importantly, we found 
that animals given Salmeterol treatment well before the appearance of symptoms in 
a long-term model of PD showed little evidence of dopaminergic neurodegeneration 
Neuroprotection
56
agonist showed beneficial effects at low concentration (10−9 M) in neurotoxicity 
and inflammatory models of PD. Salmeterol, a β2-AR agonist, can effectively serve 
as a therapeutic treatment for PD by inhibiting microglia-mediated inflamma-
tory responses in vivo. We have found that Salmeterol functions to inhibit innate 
pro-inflammatory response in both murine macrophages and microglia through its 
inhibition of the NF-κB signaling pathways [42]. We have also investigated whether 
Salmeterol is specific to neuroinflammation in PD or if it can be used as a universal 
anti-inflammatory drug against other chronic inflammatory diseases. To test this, 
we used murine macrophages stimulated with LPS from Porphyromonas gingivalis 
(PgLPS), an oral pathogen as an in vitro model for the periodontal disease. We have 
found that Salmeterol shows similar anti-inflammatory effects on PgLPS-stimulated 
macrophages [115]. Additionally, Feng et al. have also shown neuroprotective effects 
of β-arrestin2 via endogenous opioid arrest in inflammatory microglial cells [116].
10.2 Effect of β2-AR agonists on MAPK pathway
The agonist-activated β2-AR stimulates MAPK signaling pathway via noncanonical 
and G-protein independent pathway. Agonist-activated β2-AR reduces phosphoryla-
tion of ERK1/2 and p38 MAPK in macrophages stimulated with LPS. In contrast, 
β2-AR activation stimulates MAPK signaling and TNF-α, IL-12, and NO production 
in murine macrophages treated with PMA (phorbol 12-myristate-13-acetate) [73]. 
Similarly, our previous studies have shown that activation of β2-AR with the high con-
centration of agonist (up to 10−5 M) leads to sustained phosphorylation of ERK1/2 and 
enhanced production inflammatory mediators in murine microglia and macrophages 
[117]. High-dose treatment of β2-AR agonists on mixed neuroglia culture enhances 
neurotoxicity via NADPH oxidase activity in the ERK-dependent manner [118]. Like 
others, we have found that the low-doses of the β2-AR agonist Salmeterol reduces the 
MAPK activity, NF-κB activation and production of TNF-α in LPS-activated primary 
microglia [42]. We have also found that low-dose Salmeterol inhibits the phosphoryla-
tion of TAK1 (TGF-β-activated kinase1) which is an upstream regulator of NF-κB 
signaling in LPS-stimulated microglia. We have also found that Salmeterol increases 
the expression of β-arrestin2 and enhances the interaction between β-arrestin2 and 
TAB1 (TAK1-binding protein), reduced TAK1/TAB1 mediated activation of NFκB and 
expression of pro-inflammatory genes. Furthermore, silencing of β-arrestin2 abro-
gates the anti-inflammatory effects of Salmeterol in LPS-stimulated BV2 cells [119]. 
These studies suggest that the anti-inflammatory effects of Salmeterol work through 
the inhibition of pro-inflammatory pathways in microglial cells.
10.3 The β-arrestin-mediated biased effects of β2-AR agonist
Previous findings show that high dose Salmeterol enhances the expression of 
IL-1β and IL-6 mRNA and protein in unstimulated human monocytes and murine 
macrophages. These effects were β-arrestin2-dependent but PKA and NF-κB 
independent, while treatment with ERK1/2 and p38 MAPK inhibitor could reverse 
this effect [117]. This finding and several others suggest Salmeterol or other long-
acting agonist have β-arrestin “biased” signaling of β2-AR. These agonists activate 
receptors via β-arrestin signaling with a much greater extent than their effect on 
G-protein-dependent signaling [120]. Our studies suggest that a very low concen-
tration of Salmeterol does not enhance cAMP signaling and its downstream media-
tors, while it activates the β-arrestin2-mediated signaling events [42]. β-arrestin2 
has been shown as a novel regulator of IκB stability via the direct interaction of 
β-arrestin2 and IκB in HEK293 cells [121]. In addition, β-arrestin2 negatively regu-
lates the activation of NF-κB via direct binding with IκBα [122]. One study showed 
57
Adrenergic Receptors as Pharmacological Targets for Neuroinflammation and Neurodegeneration…
DOI: http://dx.doi.org/10.5772/intechopen.81343
that overexpression of β-arrestin2 significantly reduces L-DOPA-induced dyski-
nesia in animal models of PD [123]. Collectively, these studies suggest that β2-AR 
agonists can be used therapeutically not only to inhibit chronic inflammation and 
progressive degeneration of neurons, but also to treat some of the most debilitating 
neurologic symptoms in PD.
10.4 cAMP/PKA/CREB pathway induced by β2-AR
After binding with an agonist or endogenous ligand, β2-AR normally activates 
the classical cAMP-dependent signaling pathway. The downstream effect of the 
cAMP/PKA pathway is the phosphorylation and nuclear translocation of the CREB 
transcription factor which further enhances the expression of cAMP-inducible 
genes [79]. Activation of CREB via this pathway regulates the synthesis of proteins 
which are mandatory for neuronal homeostasis [124]. The classical signaling of 
β2-AR also increases the activity of PGC-1α (Peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha), which is a key regulator of mitochondrial 
biogenesis and ROS metabolism [125]. Activation of β2-AR also elevated the release 
of neurotrophic factors via cAMP/PKA/CREB pathway and provides neuroprotec-
tive benefits against degeneration [126]. An endogenous agonist of β2-AR (NE) 
affects immune cell functions, production of cytokines, and antibody secretion 
[112]. β2-AR agonists have anti-inflammatory activity and inhibit release of pro-
inflammatory mediators via cAMP/PKA/CREB pathway and also by alternate 
cAMP-dependent pathway (cAMP/Epac1/2) [42, 127, 128]. We have also found that 
pro-inflammatory effects of high-dose of Salmeterol are through cAMP/Epac path-
way, while the anti-inflammatory effects of low-dose of Salmeterol are independent 
on cAMP and Epac activation [42, 118].
11. From bench to bedside: challenges in translation to the clinic
The β2-AR agonists discussed above are FDA-approved for the treatment of 
respiratory diseases such as asthma and COPD, but none of these β2-AR agonists 
are specifically developed for PD. Although, Mittal et al. have found in a Norwegian 
population that using Salbutamol, a SABA, lower the risk of developing PD whereas 
the use of Propranolol, a β2-AR antagonist (commonly used to treat hypertension 
and certain other forms of heart disease) was associated with increased risk of PD 
[100]. Furthermore, this risk of developing PD was dependent on the duration of 
Salbutamol intake in those patients. In the patient population who used Salbutamol 
for at least 6 months, it was expected that 43 would develop PD, but only 23 patients 
were ultimately diagnosed with the disease (rate ratio 0.66). On the other hand, in 
the cohort who used Salbutamol for 2 months or less, there was no decreased risk 
of developing PD in this population [100]. In contrast, patients on Propranolol 
(which is also used as therapeutic for tremors in PD) for at least 1 year showed a 
significantly increased risk of developing PD compared to patients not on propranolol 
(rate ratio 2.2). Therefore, it is clear that patients on long-term Salbutamol (a β2-AR 
agonist) had significantly decreased the risk of developing PD, while patients on 
long-term propranolol (a β2-AR antagonist) therapy had significantly higher rates 
of PD, suggesting that β2-AR inhibition is a highly significant risk factor in develop-
ing PD. When we compared the effectiveness of Salbutamol to Salmeterol (a more 
lipophilic drug) in animal models of PD, Salmeterol was much more effective both in 
vitro and in vivo in dopaminergic neuroprotection [42]. More importantly, we found 
that animals given Salmeterol treatment well before the appearance of symptoms in 
a long-term model of PD showed little evidence of dopaminergic neurodegeneration 
Neuroprotection
58
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
compared to untreated animals. Taken together, this data suggests that administration 
of β2-AR agonists may have a profound preventative effect on the development of 
PD. Since the blood-brain-barrier penetration is a major obstacle in the development 
of therapeutics targeting CNS disorders, it will be important to consider the impor-
tance of lipophilic properties, concentration within the CNS, as well as the specific-
ity, half-life and safety in using β2-AR agonists in older patients before and after 
the initial appearance of symptoms associated with PD. Consequently, these drugs 
require further investigation in a large cohort study to assess their utility as a potential 
therapeutic for PD and other neurodegenerative diseases.
12. Conclusion
Natural or synthetic activation or inhibition of the β2-AR can have profound effects 
on the development and progression of Parkinson’s disease, a chronic neurodegenera-
tive disorder which involves both neuroinflammatory and cellular mechanisms in 
dopaminergic neurotoxicity. It is now clear that the therapeutic use of β2-AR agonists 
can both inhibit the cause of neurodegeneration and activate a mechanism that can 
enhance recovery of patients with this disease, and serves as an important new thera-
peutic approach to the treatment of chronic neurodegenerative disorders.
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Protecting the Aging Retina
Shen Nian and Amy C.Y. Lo
Abstract
Aging retina, notably the aging macula, is prone to develop degenerative 
diseases, such as age-related macular degeneration (AMD), the leading cause of 
visual loss in individuals aged 65 or above in developed countries. However, current 
treatments are very limited. Since degeneration, dysfunction, and death of retinal 
neurons are demonstrated in the pathogenesis of AMD, neuroprotective strategies 
could serve as a possible way to treat AMD. In this chapter, we will briefly introduce 
risk factors, pathophysiology, affected neurons, classification, clinical manifesta-
tion, and current treatments of AMD. Finally, neuroprotection in both AMD animal 
models and patients will be discussed.
Keywords: neuroprotection, degeneration, photoreceptor, age-related macular 
degeneration, vision loss
1. Introduction
Retina, which forms the innermost layer of the eyeball, is considered as the end 
organ of the central nervous system. Macula, located in the central and posterior 
part of retina, possesses the highest concentration of photoreceptors and, therefore, 
is responsible for central vision and high-resolution visual acuity (VA). The fovea 
is a tiny pit in the center of the macula and in charge of the central, sharpest vision. 
Unfortunately, the macula is more prone to experience degenerative changes with 
age, such as age-related macular degeneration (AMD), leading to visual impairment.
Due to the increase of life expectancy worldwide, the size of aging population 
will become larger in the coming decades [1]. According to “World Population 
Prospects: The 2017 Revision” released by the United Nations, the number of per-
sons aged 60 or above will more than double, from 962 million in 2017 to 2.1 billion 
by 2050. The number of people aged 80 or above is predicted to triple by 2050, from 
137 million in 2017 to 425 million by 2050 [2]. In mainland of China, people aged 
above 65 represented 11.4% of the total population in 2017 [3]. As a consequence, 
the increasing prevalence of AMD will be foreseen globally in the future.
In 2015, it was estimated that AMD was the fourth leading cause of blindness 
and the third most common cause of moderate to severe visual impairment globally 
[4]. The meta-analysis performed by Wong and collaborators has estimated that 
the number of persons with AMD will increase from 196 million in 2020 to 288 
million in 2040 worldwide [5]. A similar trend is observed in the projected number 
of individuals affected by AMD in China, rising from 31.23 million in 2020 to 55.19 
million in 2050 [6]. In addition, the prevalence of late AMD did not show signifi-
cant difference among Asian, European, and North American studies, whereas the 
number of individuals with early AMD was more in European and North American 
studies than in Asian studies [7].
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2. Anatomy and function of the retina
The eye is composed of three layers, which are the inner retina layer, middle 
vascular choroid layer, and outer fibrous sclera layer, respectively. Retina, the inner-
most layer of the eye, consists of two parts: the inner transparent neurosensory 
retina and outer pigmented epithelial layer—the retinal pigment epithelium (RPE). 
There is a potential space between neural retina and RPE, called subretinal space. 
In the neural retina, the neural cell bodies are situated in three layers (Figure 1), 
including the outer nuclear layer (ONL) occupied with nuclei of photoreceptors; 
the inner nuclear layer (INL) filled with nuclei of horizontal, bipolar, and most of 
the amacrine cells; as well as ganglion cell layer (GCL) containing nuclei of retinal 
ganglion cells and the rest of displaced amacrine cells. Additionally, axons and den-
drites of these retinal neurons constitute two synaptic layers: the inner plexiform 
layer (IPL) and outer plexiform layer (OPL) [8]. The RPE cells form a continuous 
polarized cell monolayer with its apical surface adjacent to the outer segment apices 
of the photoreceptors and its basal aspect lying on supportive substrate Bruch’s 
membrane.
Retinal neurons are mainly distributed in three layers: ONL with nuclei of 
photoreceptors; INL with nuclei of horizontal, bipolar, and most of the amacrine 
cells; and GCL with nuclei of retinal ganglion cells and the rest of displaced ama-
crine cells. Additionally, axons and dendrites of these retinal neurons constitute two 
synaptic layers, including IPL and OPL [8].
Photoreceptors are divided into two types: rods, which are dominated in the 
peripheral retina and responsible for dim light vision and detecting movement 
and contrast, and cones, which are dominated in the macula, especially the fovea 
(only cones), and are responsible for bright light vision and sensing color vision 
Figure 1. 
Retinal layers of the human eye.
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and resolution. Outer segments of the photoreceptor are generated by the cell body, 
and the distal parts of outer segments are phagocytosed by RPE every day. There 
are abundant mitochondria in inner segments to supply energy for these cells with 
high metabolic rate. Bruch’s membrane, where the RPE cells are tightly attached, 
consists of five layers including, from inner to outer, the RPE basal lamina, inner 
collagenous zone, elastic layer, outer collagenous zone, and basement membrane of 
the choriocapillaris [9].
In brief, the function of the retina is to convert the external light signals into 
electrical impulses by photoreceptors. The impulses, which are partly integrated 
locally by horizontal cells and amacrine cells, are then processed by bipolar cells 
and sent to ganglion cells which further transmit them to the brain. Moreover, 
RPE is crucial for maintaining the microenvironment of neural retina by exchang-
ing nutrients and wastes between neural retina and choroid, secreting numerous 
growth factors, phagocytosing shed photoreceptor outer segments (POS), absorb-
ing light and converting all-trans-retinal into 11-cis-retinal [10]. Any defects in any 
of these functions may result in retinal degeneration, deficits of visual function, 
and eventually loss of sight.
3. Current knowledge of AMD
3.1 Classification and clinical manifestations
A variety of classification systems are employed for both clinical and basic 
research of AMD. However, the most commonly used classification is the one 
defined by the Age-Related Eye Disease Study (AREDS) in terms of the characteris-
tics of drusen (yellow deposits in the macula), abnormal hypo- or hyperpigmenta-
tion in the first eye, and how it affected the fellow eye. Based on the above criteria, 
AMD is classified into 4 categories: (1) no clinical manifestation of AMD if there 
was no drusen or only non-extensive, small drusen (<63 μm in diameter) in both 
eyes; (2) mild AMD classified by extensive small drusen, non-extensive intermedi-
ate drusen (63–124 μm in diameter), or abnormalities of pigments in at least one 
eye; (3) intermediate AMD characterized with large drusen (>124 μm in diameter), 
extensive intermediate drusen, or noncentral geographic atrophy (GA) in at least 
one eye; (4) advanced AMD defined as central GA or choroidal neovascularization 
(CNV) resulting in VA less than 20/32 [11–13].
There are two clinical types of advanced AMD: a non-exudative or atrophic 
(dry) form, accounting for 90% of AMD, and an exudative (wet) form, accounting 
for only 10% of AMD. The atrophic form is characterized by progressive degen-
eration of RPE cells and photoreceptors in the macula, affecting central vision to 
varying degrees over months or years [14, 15]. The exudative form is associated with 
CNV in the submacular area and subsequent retinal hemorrhage due to leakage of 
these newly formed fragile blood vessels, leading to severe central vision loss within 
a very short period of time [15].
At the early stage of AMD, patients are normally asymptomatic and may be diag-
nosed by the presence of round, yellowish drusen through the routine ophthalmo-
logical examinations. Patients with CNV usually suffer from sudden loss of vision, 
describing unexpected deterioration of central visual field, distorted straight line 
(metamorphopsia), and/or a dark area in the central visual field (scotoma). On 
fundus examination, macular edema and hemorrhage are observed and fluorescein 
angiography shows leakage. In non-exudative AMD, it takes years for patients to 
develop visual loss gradually, and fundus examination shows a well-defined RPE 
atrophic area with depigmentation (Figure 2) [15].
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A number of risk factors are thought to be related to the pathogenesis of AMD, 
such as increasing age, smoking, family history of AMD, overweight or obesity, 
cataract and cataract surgery, eye exposure to the sunlight, etc. Of these factors, age 
is the strongest risk factor, with around 30% of cases older than 85 years diagnosed 
with AMD in US [17, 18]. The risk of developing AMD was reported to be more than 
triple in patients above 75 years than patients aged between 65 and 74 years [18, 19]. 
In populations of European ancestry, the projected prevalence of late AMD was 
0.08% at age 50, 0.33% at age 60, 1.38% at age 70, 5.60% at age 80, and 20.10% at 
age 90, respectively [20]. Similarly, the estimated prevalence of any AMD increased 
from 2.44% in persons at the age of 45–49 years to 18.98% in persons at the age of 
85–89 years [6].
Ethnicity and family history are also strongly related with AMD prevalence. The 
highest rate was reported in Caucasians, followed by Hispanics and Asians, while 
African Americans showed the lowest morbidity rate [21]. Increased risk of AMD 
was observed in individuals with positive family history, approximately three to six 
times higher than it was for those from the general population [22]. Furthermore, 
genetic studies have revealed 34 loci linked to AMD until now, of which comple-
ment factor H (CFH) on 1q31.3, age-related maculopathy susceptibility 2 (ARMS2) 
on 10q26, and CFB/C2 on 6q21.3 were the most discussed genes [15, 23, 24].
The strong relationship between cigarette smoking and development of AMD 
has been widely accepted [17, 25, 26]. Several studies revealed that current smoking 
was strongly associated with the progression of AMD [27]. Moreover, past smoking 
was reported to be a risk factor to develop AMD as well, especially in the rural areas 
[28]. There was an increased risk for individuals with high intake of several types of 
fat, such as omega-6 polyunsaturated fatty acids and saturated fats, whereas diets 
rich in monounsaturated fatty acids might reduce the prevalence of AMD [29]. 
Inadequate uptake of antioxidants also resulted in AMD, and numerous studies have 
suggested that antioxidant supplementation, including vitamins, lutein, zeaxan-
thin, beta-carotene, zinc, etc., helped to halt the progression of AMD to some 
extent [12, 30, 31].
The effects of sunlight exposure on the occurrence of AMD are controversial. A 
study performed by Khan and colleagues demonstrated that no significant associa-
tion between light exposure and AMD was observed when comparing patients at 
the end stage of AMD with spouse controls [32]. However, other studies suggested 
that damages induced by either ultraviolet (UV) or visible sunlight might lead to 
Figure 2. 
Representative fundus of AMD patients. (A) Non-exudative form of AMD with a well-defined atrophic 
region and (B) exudative form of AMD with retinal hemorrhage and macula edema [16].
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AMD [33–35]. There was conflicting evidence regarding the role of cataract surgery 
in the progression of AMD [36]. Earlier, a large population-based research indicated 
a stronger relationship between cataract surgery with the development of end-stage 
AMD, especially neovascular AMD, in older patients [36, 37]. On the contrary, 
several recent clinical studies failed to demonstrate similar results [36, 38].
In addition to the risk factors mentioned above, other relevant factors included 
hypertension, cardiovascular diseases, iris color, hyperlipidemia, diabetes, alcohol 
consumption, and so on [22]. According to a systematic review of 18 prospective 
and cross-sectional studies and 6 case-control studies engaging 113,780 individuals, 
advancing age, cigarette smoking, previous cataract surgery, and family history 
of AMD were considered as the strong risk factors of AMD, while hypertension, 
cardiovascular disease, overweight or obesity, and elevated plasma fibrinogen were 
regarded as the moderate risk factors [17].
3.3 Pathophysiology
AMD is regarded as a complicated multifactorial disease, although the exact 
pathogenesis still remains poorly understood. It is generally recognized that impair-
ment of aged RPE cell functions served an important role in the progression of 
non-exudative AMD. The aged RPE cells were less efficient in phagocytosing and 
degrading POS, resulting in the progressive accumulation of lipofuscin consisting 
of phagosomal and lysosomal constituents in the cytoplasm. The cytotoxic elements 
in lipofuscin, such as bisretinoid fluorophore, were able to generate reactive oxygen 
species leading to the damage of DNA, lipids, and proteins [39].
Another age-dependent change was the formation of focal extracellular yellow 
deposits known as drusen, the hallmark of AMD, between the RPE and Bruch’s 
membrane. Accumulation of drusen relied on the changes in the permeability of 
Bruch’s membrane due to the decline of RPE cell functions with aging [40]. In 
addition, it has been estimated that breakdown of choriocapillaris, which was next 
to RPE and Bruch’s membrane, resulted in insufficient elimination of extracel-
lular wastes causing drusen [41]. According to their shape and size, drusen are 
separated into small (<125 μm), round hard drusen with well-defined borders, and 
relatively large, (125–250 μm) soft drusen with poorly defined borders. Soft drusen, 
especially with depigmentation or pigment abnormalities, was considered to be an 
indication to give rise to severe vision loss at the late stage.
The mechanism of drusen causing adjacent RPE and photoreceptors’ damage 
was not only dependent on the structural disturbance of RPE and photoreceptor by 
them, but also on the indirect effects through stimulation of local inflammation and 
immune system [42, 43]. Components in complement pathway and inflammatory 
processes were observed in drusen and aged RPE cells that are closely related to 
drusen [42]. It was demonstrated that in AMD, genetic variation of factor H gene 
(HF1/CFH) induced the abnormal activities of factor H (the inhibitor of comple-
ment cascade) in drusen, leading to the activation of complement pathway and 
subsequent inflammation in subretinal tissues [44]. Furthermore, in AMD patients, 
decreased CFH level was reported in smokers than nonsmokers, suggesting the 
activation of complement cascade might contribute to the significantly higher risk 
of AMD progression in cases with smoking [45].
DICER1, the ribonucleic acid (RNA)-cleaving enzyme, was decreased in RPE 
cells in cases with non-exudative AMD. A group of researchers in the University 
of Kentucky suggested that the lower level of DICER1 led to the lower rate of Alu 
RNA degradation in RPE cells. Therefore, accumulation of Alu RNA in cytoplasm 
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Figure 2. 
Representative fundus of AMD patients. (A) Non-exudative form of AMD with a well-defined atrophic 
region and (B) exudative form of AMD with retinal hemorrhage and macula edema [16].
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AMD [33–35]. There was conflicting evidence regarding the role of cataract surgery 
in the progression of AMD [36]. Earlier, a large population-based research indicated 
a stronger relationship between cataract surgery with the development of end-stage 
AMD, especially neovascular AMD, in older patients [36, 37]. On the contrary, 
several recent clinical studies failed to demonstrate similar results [36, 38].
In addition to the risk factors mentioned above, other relevant factors included 
hypertension, cardiovascular diseases, iris color, hyperlipidemia, diabetes, alcohol 
consumption, and so on [22]. According to a systematic review of 18 prospective 
and cross-sectional studies and 6 case-control studies engaging 113,780 individuals, 
advancing age, cigarette smoking, previous cataract surgery, and family history 
of AMD were considered as the strong risk factors of AMD, while hypertension, 
cardiovascular disease, overweight or obesity, and elevated plasma fibrinogen were 
regarded as the moderate risk factors [17].
3.3 Pathophysiology
AMD is regarded as a complicated multifactorial disease, although the exact 
pathogenesis still remains poorly understood. It is generally recognized that impair-
ment of aged RPE cell functions served an important role in the progression of 
non-exudative AMD. The aged RPE cells were less efficient in phagocytosing and 
degrading POS, resulting in the progressive accumulation of lipofuscin consisting 
of phagosomal and lysosomal constituents in the cytoplasm. The cytotoxic elements 
in lipofuscin, such as bisretinoid fluorophore, were able to generate reactive oxygen 
species leading to the damage of DNA, lipids, and proteins [39].
Another age-dependent change was the formation of focal extracellular yellow 
deposits known as drusen, the hallmark of AMD, between the RPE and Bruch’s 
membrane. Accumulation of drusen relied on the changes in the permeability of 
Bruch’s membrane due to the decline of RPE cell functions with aging [40]. In 
addition, it has been estimated that breakdown of choriocapillaris, which was next 
to RPE and Bruch’s membrane, resulted in insufficient elimination of extracel-
lular wastes causing drusen [41]. According to their shape and size, drusen are 
separated into small (<125 μm), round hard drusen with well-defined borders, and 
relatively large, (125–250 μm) soft drusen with poorly defined borders. Soft drusen, 
especially with depigmentation or pigment abnormalities, was considered to be an 
indication to give rise to severe vision loss at the late stage.
The mechanism of drusen causing adjacent RPE and photoreceptors’ damage 
was not only dependent on the structural disturbance of RPE and photoreceptor by 
them, but also on the indirect effects through stimulation of local inflammation and 
immune system [42, 43]. Components in complement pathway and inflammatory 
processes were observed in drusen and aged RPE cells that are closely related to 
drusen [42]. It was demonstrated that in AMD, genetic variation of factor H gene 
(HF1/CFH) induced the abnormal activities of factor H (the inhibitor of comple-
ment cascade) in drusen, leading to the activation of complement pathway and 
subsequent inflammation in subretinal tissues [44]. Furthermore, in AMD patients, 
decreased CFH level was reported in smokers than nonsmokers, suggesting the 
activation of complement cascade might contribute to the significantly higher risk 
of AMD progression in cases with smoking [45].
DICER1, the ribonucleic acid (RNA)-cleaving enzyme, was decreased in RPE 
cells in cases with non-exudative AMD. A group of researchers in the University 
of Kentucky suggested that the lower level of DICER1 led to the lower rate of Alu 
RNA degradation in RPE cells. Therefore, accumulation of Alu RNA in cytoplasm 




In exudative AMD, local nonspecific inflammation stimulated the upregulation 
of angiogenic factors, such as vascular endothelial growth factor (VEGF), and/or 
downregulation of anti-angiogenic factors, such as pigment epithelium-derived fac-
tor (PEDF), causing CNV development in the avascular outer 1/3 retina. The new 
vessels are fragile, thus macular edema and hemorrhage occur due to the leakage 
of these new blood vessels, which finally resulted in the fibrovascular scars in the 
macula [41, 48].
3.4 Affected neurons
Due to the dysfunction of aged RPE cells, especially the failure of POS phago-
cytosis, photoreceptor loss occurs subsequently. Although the most remarkable 
clinical and pathological injuries are present in RPE and its underlying Bruch’s 
membrane, it is the structural and functional disruptions, even the death of 
photoreceptors, via either atrophic or neovascular process, that take responsibilities 
for the visual impairment in AMD. Furthermore, the condition of photoreceptors 
directly reflects the significance of lesions in RPE/Bruch’s membrane complex.
It is crucial to identify which type of photoreceptors are most severely damaged 
in AMD, not only for the potential therapeutic strategies targeting the most affected 
cells, but also for investigation of mechanism of these pathological changes. The 
rate of rod and cone degeneration is representative in different situations affecting 
photoreceptors. In aging retina without age-related maculopathy, the number of 
cells in the cone-dominated fovea remained stable, while the number of rods in the 
parafovea was reduced by 30% [49]. In both non-exudative and exudative forms of 
AMD, photoreceptors were lost. In addition, more rod loss was observed than that 
of cones; gradually, only degenerated cones were left; finally, all photoreceptors 
might die [50]. The pathological changes mentioned above were consistent with the 
functional research exhibiting that scotopic sensitivity decreased more than phot-
opic sensitivity in cases with AMD [51]. Maeda and colleagues revealed the apopto-
sis of photoreceptors after RPE damage caused by intravitreal injection of ornithine 
in rats, indicating the important role of RPE cells in maintaining photoreceptor 
integrity [52]. In AMD patients, apoptotic photoreceptors and RPE cells (TUNEL 
positive) were observed as well. Most of TUNEL-positive photoreceptors were rods 
and located at the edge of RPE atrophy. Moreover, Fas was upregulated in apoptotic 
photoreceptors, indicating Fas/FasL might be involved in the apoptosis process [53]. 
Studies performed by Kim and collaborators demonstrated that significant reduc-
tion of photoreceptors was shown in the areas where RPE cells were totally lost in 
GA, and where disciform scar formed in wet AMD [54, 55]. In terms of disciform 
scar, thickness of the scar was closely associated with photoreceptor loss, which 
means that the thicker the disciform scar, the less photoreceptors survived [56].
In addition to photoreceptors, other retinal neurons are also affected. Joshua 
et al. first reported that TUNEL-positive cells were detected in the inner side of 
INL, indicating that these cells might be amacrine cells [53]. In cases with GA, 
retinal ganglion cells were significantly decreased by 30.7% compared to age-
matched control. However, cell nuclei in INL were not significantly different [54]. 
In wet form of AMD, a decrease of ganglion cells and increase of cells in INL were 
observed, but there was no significant difference [55].
3.5 Current treatments
Several treatments have been adopted for AMD management. However, current 
therapeutics can only slow the progression of the disease, trying to delay the onset 
of vision loss as much as possible.
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To date, there are no approved drugs for the dry form of AMD. Therefore, 
much effort has been made to reduce risk factors. Among various risk factors, 
oxidative stress induced by inflammation, light exposure, and so on is considered 
as one of the most important risk factors for the occurrence and progression of 
AMD. Numerous studies have been conducted to evaluate the relationship between 
antioxidant nutrition supplementation and AMD. In the Age-Related Eye Disease 
Study (AREDS), it was demonstrated that oral dietary supplementation containing 
vitamin C (500 mg/day) and E (400 IU/day), zinc oxide (80 mg/day), cupric oxide 
(2 mg/day), and beta-carotene (15 mg/day) can decrease the risk of development 
of AMD from intermediate stage to advanced stage [11]. Since beta-carotene was 
observed to increase the risk of lung cancer in cigarette smokers, and 80 mg/day 
zinc is out of tolerance for individuals, there were elimination of beta-carotene, 
decreased dose of zinc (25 mg/day), and adding of lutein and zeaxanthin in the 
AREDS2 formula [12, 57, 58]. A 10% reduction in developing to advanced AMD was 
present in patients treated with AREDS2 formula containing lutein and zeaxanthin 
[59]. In addition, healthy diet rich in fish, green leafy vegetables, and nuts together 
with healthy lifestyle are strongly recommended to reduce AMD risk factors [15].
For the wet form of AMD, therapies mainly focus on halting the progression of 
CNV. Thermal laser photocoagulation is the first treatment to stop the progression 
of CNV successfully, but with no significant vision improvement and high recur-
rence of CNV. Photodynamic therapy with verteporfin can selectively damage the 
CNV tissue without additional injuries of neighboring tissue, but this therapy has 
no effects on visual improvement either. In terms of upregulation of VEGF in the 
development of CNV, intravitreal injection of anti-VEGF drugs has been widely 
used by ophthalmologists as a standard treatment. Anti-VEGF drugs (Pegaptanib 
sodium, Ranibizumab, and Bevacizumab) for exudative AMD have demonstrated 
exciting results: the vision in the majority of patients remained stable for 1 year, of 
which 40% of patients had visual improvement. Surgical intervention to remove 
CNV and submacular hemorrhage did not improve VA, which is the result of recur-
rence of CNV [15, 60].
4.  Neuroprotection in AMD experimental studies and clinical 
approaches
Neuroprotection comprises a large number of therapeutic interventions to 
improve survival of neurons by modifying the structure and function of neurons, 
and/or their microenvironment. Initially, neuroprotective therapies are focused on 
central nervous system diseases including stroke, Alzheimer’s disease, Parkinson’s 
disease, etc. Since retina is regarded as the end part of central nervous system, 
a series of neuroprotective strategies has been applied to prevent vision loss by 
protecting retinal neurons. Furthermore, tremendous neuroprotective strategies are 
under investigation in both experimental and clinical research.
4.1 Studies in animal models
Neurotrophic factors, belonging to the family of growth factors, have the 
ability to promote survival of retinal neurons. Ciliary neurotrophic factor (CNTF) 
is one of the most extensively studied neurotrophic factors for neural retina 
protection. La Vail and collaborators first reported that intraocular injection of 
CNTF obviously prevented photoreceptor death from light-induced damage in 
Sprague Dawley rats [61]. Subsequently, intravitreal injection of adenoviral vec-
tor containing CNTF cDNA in rd1 mice, a naturally occurring mouse model for 
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AMD, photoreceptors were lost. In addition, more rod loss was observed than that 
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might die [50]. The pathological changes mentioned above were consistent with the 
functional research exhibiting that scotopic sensitivity decreased more than phot-
opic sensitivity in cases with AMD [51]. Maeda and colleagues revealed the apopto-
sis of photoreceptors after RPE damage caused by intravitreal injection of ornithine 
in rats, indicating the important role of RPE cells in maintaining photoreceptor 
integrity [52]. In AMD patients, apoptotic photoreceptors and RPE cells (TUNEL 
positive) were observed as well. Most of TUNEL-positive photoreceptors were rods 
and located at the edge of RPE atrophy. Moreover, Fas was upregulated in apoptotic 
photoreceptors, indicating Fas/FasL might be involved in the apoptosis process [53]. 
Studies performed by Kim and collaborators demonstrated that significant reduc-
tion of photoreceptors was shown in the areas where RPE cells were totally lost in 
GA, and where disciform scar formed in wet AMD [54, 55]. In terms of disciform 
scar, thickness of the scar was closely associated with photoreceptor loss, which 
means that the thicker the disciform scar, the less photoreceptors survived [56].
In addition to photoreceptors, other retinal neurons are also affected. Joshua 
et al. first reported that TUNEL-positive cells were detected in the inner side of 
INL, indicating that these cells might be amacrine cells [53]. In cases with GA, 
retinal ganglion cells were significantly decreased by 30.7% compared to age-
matched control. However, cell nuclei in INL were not significantly different [54]. 
In wet form of AMD, a decrease of ganglion cells and increase of cells in INL were 
observed, but there was no significant difference [55].
3.5 Current treatments
Several treatments have been adopted for AMD management. However, current 
therapeutics can only slow the progression of the disease, trying to delay the onset 
of vision loss as much as possible.
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To date, there are no approved drugs for the dry form of AMD. Therefore, 
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oxidative stress induced by inflammation, light exposure, and so on is considered 
as one of the most important risk factors for the occurrence and progression of 
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(2 mg/day), and beta-carotene (15 mg/day) can decrease the risk of development 
of AMD from intermediate stage to advanced stage [11]. Since beta-carotene was 
observed to increase the risk of lung cancer in cigarette smokers, and 80 mg/day 
zinc is out of tolerance for individuals, there were elimination of beta-carotene, 
decreased dose of zinc (25 mg/day), and adding of lutein and zeaxanthin in the 
AREDS2 formula [12, 57, 58]. A 10% reduction in developing to advanced AMD was 
present in patients treated with AREDS2 formula containing lutein and zeaxanthin 
[59]. In addition, healthy diet rich in fish, green leafy vegetables, and nuts together 
with healthy lifestyle are strongly recommended to reduce AMD risk factors [15].
For the wet form of AMD, therapies mainly focus on halting the progression of 
CNV. Thermal laser photocoagulation is the first treatment to stop the progression 
of CNV successfully, but with no significant vision improvement and high recur-
rence of CNV. Photodynamic therapy with verteporfin can selectively damage the 
CNV tissue without additional injuries of neighboring tissue, but this therapy has 
no effects on visual improvement either. In terms of upregulation of VEGF in the 
development of CNV, intravitreal injection of anti-VEGF drugs has been widely 
used by ophthalmologists as a standard treatment. Anti-VEGF drugs (Pegaptanib 
sodium, Ranibizumab, and Bevacizumab) for exudative AMD have demonstrated 
exciting results: the vision in the majority of patients remained stable for 1 year, of 
which 40% of patients had visual improvement. Surgical intervention to remove 
CNV and submacular hemorrhage did not improve VA, which is the result of recur-
rence of CNV [15, 60].
4.  Neuroprotection in AMD experimental studies and clinical 
approaches
Neuroprotection comprises a large number of therapeutic interventions to 
improve survival of neurons by modifying the structure and function of neurons, 
and/or their microenvironment. Initially, neuroprotective therapies are focused on 
central nervous system diseases including stroke, Alzheimer’s disease, Parkinson’s 
disease, etc. Since retina is regarded as the end part of central nervous system, 
a series of neuroprotective strategies has been applied to prevent vision loss by 
protecting retinal neurons. Furthermore, tremendous neuroprotective strategies are 
under investigation in both experimental and clinical research.
4.1 Studies in animal models
Neurotrophic factors, belonging to the family of growth factors, have the 
ability to promote survival of retinal neurons. Ciliary neurotrophic factor (CNTF) 
is one of the most extensively studied neurotrophic factors for neural retina 
protection. La Vail and collaborators first reported that intraocular injection of 
CNTF obviously prevented photoreceptor death from light-induced damage in 
Sprague Dawley rats [61]. Subsequently, intravitreal injection of adenoviral vec-
tor containing CNTF cDNA in rd1 mice, a naturally occurring mouse model for 
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retinal degenerative diseases, demonstrated the reduction of photoreceptor loss, 
conservation of ONL thickness, and increase of photoreceptor segments’ length. 
Moreover, the amplitudes of a-wave and b-wave in electroretinogram (ERG) were 
significantly increased compared with those of the control group, suggesting the 
preservation of retinal functions [62, 63]. Later, long-term protective effects of 
photoreceptors were shown using adeno-associated virus to deliver CNTF to the 
retina [64]. In order to sustainably deliver neurotrophic factors, encapsulated 
human RPE cells secreting CNTF were transplanted into the vitreous of rcd1 dog 
(a dog model of retinal degeneration). A significant increase of ONL thickness was 
observed in the treated eye as a result of continuous release of CNTF at the nano-
gram level [65]. No adverse effects were exhibited in the retina of transplanted eyes 
during the whole experiment period (7 weeks). In addition, CNTF was proved to 
protect loss of cone outer segments, an early sign of cone degeneration, indicating 
that CNTF could not only slow or halt progression of degeneration but also might 
reverse degeneration [66].
Placental growth factor (PIGF), one of the members of vascular endothelial 
growth factor family, was believed to prevent neuronal injury in the brain. In the 
retina, the role of PIGF was exhibited quite differently in in vitro and in vivo studies. 
Blue light-induced murine photoreceptor cell death was significantly attenu-
ated after the treatment of PIGF by suppressing caspase-3/7 activity through the 
mitogen-activated protein kinase (MEK) and phosphoinositide 3-kinase (PI3K) 
pathway. Anti-PIGF antibody eliminated these protective effects [67]. However, 
in the light-induced retina-damaged mouse model, PIGF induced decreased ONL 
thickness and dysfunction of retina. Anti-PIGF antibody diminished neuroretinal 
injury and disruption of RPE cell-cell junctions after exposure to the white light for 
3 h [68]. The opposite effects of PIGF and its antibody in mice were later found to 
be due to the hyperpermeability of RPE induced by PIGF, leading to the breakdown 
of retina-blood barrier and subsequent damages [68].
Ursodeoxycholic acid (UDCA) and its taurine-conjugated derivative taurourso-
deoxycholic acid (TUDCA) were first found in the bile acid of hibernating bears. 
They have been used for liver detoxification, dissolution of gallstone and kidney 
stone, suppression of convulsions, and visual improvement in traditional Chinese 
medicine for a very long time. According to the theory of modern medicine, UDCA 
and TUDCA exhibit neuroprotective effects through prevention of cell apoptosis 
[69]. TUDCA treatment significantly preserved the number and structure of 
photoreceptors and retinal functions in different murine models of photoreceptor 
degeneration, including rd10 mice, rd1 mice, BALB/c mice, Bardet-Biedl syndrome 
type 1 mice, and transgenic P23H rats [69]. Furthermore, TUDCA manifested 
greater protective effects in cones [70]. In vitro studies using photoreceptor 661 W 
cells revealed that reduced endoplasmic reticulum (ER) stress and improved traf-
ficking of cyclic nucleotide-gated channels in cones contributed to neuroprotective 
effects of TUDCA [71]. In addition, TUDCA improved phagocytosis of POS in 
H2O2-treated RPE cells via activating Mer tyrosine kinase receptor (MerTK), which 
indirectly protected photoreceptors [72].
Endogenous and exogenous progesterone have been certified to have neuro-
protective effects in brain and retina for several decades. A broad range of studies 
have been conducted in either light-damaged or genetic murine models of retinal 
degeneration, demonstrating improvement in photoreceptor survival, decreased 
gliosis, and reduced retinal dysfunction after administration of progesterone or 
synthetic progestins [69]. A group of researchers in Spain revealed that rd1 mice 
orally administered with progesterone (100 mg/kg body weight) at postnatal 
day 7 (P7) exhibited significantly decreased number of apoptotic cells in ONL in 
the far peripheral retina and increased amplitude of ERG b-wave at P15, but no 
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significant change was observed at P17. There was also a transient reduced gliosis 
in the treated rd1 mice [73]. Similar results were observed with oral administration 
of synthetic progestin, known as the FDA-approved Norgestrel, showing reduction 
of photoreceptor death by 70 and 75% in light-damaged mouse model and rd10 
mice, respectively [74]. The rescue effects were achieved by increasing production 
of basic fibroblast growth factor and its downstream pro-survival reactive oxygen 
species [74, 75].
Crystallins, critical family members of small heat shock proteins, have been 
identified to have novel functions in both retina and RPE as in the lens, such as anti-
apoptosis and anti-inflammation. αB-Crystallin is secreted in exosomes released 
from apical surface of polarized RPE cells and accumulates in the matrix among 
photoreceptors, and therefore may protect neighboring RPE and photoreceptors 
[76]. RPE cells in αB-crystallin knockout mice exhibited high susceptibility to 
oxidative stress and endoplasmic reticulum stress compared to the RPE cells from 
wild-type mice. Furthermore, RPE cells overexpressing αB-crystallin were more 
resistant to apoptosis, indicating the protective effects of αB-crystallin [77]. In the 
mouse model of AMD induced by sodium iodate (NaIO3), absence of αB-crystallin 
accelerated RPE apoptosis with subsequent death of photoreceptors through 
upregulation of AKT phosphorylation and expression of peroxisome proliferator-
activator receptor-γ, suggesting αB-crystallin, especially the small peptide called 
mini cry, may play an important role in the protection of retinal degeneration [77]. 
In order to prolong the life of mini cry in the vitreous, free mini cry was fused to 
form an elastin-like polypeptide (ELP), which could be detected in the vitreous for 
up to 2 weeks. One intravitreal injection of ELP-linked peptide prevented RPE cells 
from apoptosis, inhibited activation of caspase-3 activation, and protected neural 
retina for up to 1 month after NaIO3 challenge [78].
NF-E2-related factor 2 (Nrf2) is a transcription factor that regulates antioxidant 
responses in many tissues and cell types, providing protection against oxidative 
stress. Under the oxidative stress, Nrf2 is translocated from cytoplasm to nucleus, 
and subsequently binds to the corresponding sites to activate transcription of a wide 
range of antioxidant genes. In the central nervous system, Nrf2 was proved to slow 
the neurodegeneration by means of antioxidative stress and neuroinflammation 
[79]. In the mice undergoing optic nerve crush (an animal model of glaucoma), 
retinal ganglion cells were significantly decreased than in the wild-type mice. 
With the treatment of Nrf2 activator, retinal ganglion cell loss was decreased by 
upregulating gene expression of antioxidant and phase II detoxifying enzymes [80]. 
After retinal ischemia-reperfusion injury, Nrf2 knockout mice showed greater loss 
of retinal ganglion cells when compared with the wild-type mice. Moreover, after 
ischemia-reperfusion injury, Nrf2 activator increased survival of retinal ganglion 
cells in wild-type mice, but not Nrf2 knockout mice, indicating the neuroprotective 
effects of Nrf2 [81]. An in vitro study has demonstrated that siRNA knockdown of 
Nrf2 led to significant increase of reactive oxygen species and cell death after blue 
light exposure in murine photoreceptor cells, suggesting that Nrf2 could be used to 
protect photoreceptors in AMD and other retinal degeneration [82].
There is no direct evidence that dopamine protects retinal neurons through anti-
inflammation, apoptosis, and oxidative stress. However, decreased expression of 
dopamine may play a negative role in neuron survival in the brain [83]. Thus, dopa-
mine receptor agonists may achieve the goal to promote retinal neuron survival and 
function by restoring the lost dopamine resulting from certain diseases. Dopamine 
receptor agonist pramipexole was shown to ameliorate structural and functional 
injuries in the light-damaged mice, exhibiting decreased photoreceptor death, 
damage of photoreceptor outer and inner segments, TUNEL-positive cells in ONL, 
and preservation of a-wave and b-wave in ERG [84]. Additionally, pramipexole 
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protect photoreceptors in AMD and other retinal degeneration [82].
There is no direct evidence that dopamine protects retinal neurons through anti-
inflammation, apoptosis, and oxidative stress. However, decreased expression of 
dopamine may play a negative role in neuron survival in the brain [83]. Thus, dopa-
mine receptor agonists may achieve the goal to promote retinal neuron survival and 
function by restoring the lost dopamine resulting from certain diseases. Dopamine 
receptor agonist pramipexole was shown to ameliorate structural and functional 
injuries in the light-damaged mice, exhibiting decreased photoreceptor death, 
damage of photoreceptor outer and inner segments, TUNEL-positive cells in ONL, 
and preservation of a-wave and b-wave in ERG [84]. Additionally, pramipexole 
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inhibited ARPE-19 cell (an immortalized RPE cell line) death after H2O2 treatment, 
suggesting its antioxidative effects [84].
Regular general physical exercise is not only a part of healthy life style, but also 
a rehabilitation strategy showing neuroprotective effects in numerous diseases. 
Recently, exercise has been proven to be neuroprotective in animal models of retinal 
degeneration [85–87]. Wild-type BALB/c mice were forced to exercise for 5 days/
week for 2 weeks before being exposed to bright light. Exercised mice showed 
greater improved amplitude of ERG b-wave and photoreceptor nuclei than the 
mice without exercise after light exposure [85]. In order to exclude the impact of 
stress caused by forced exercise, voluntary wheel running was adopted in rd10 
mice, which also demonstrated protection of VA, and the number of cones and total 
photoreceptors [86]. No matter if it was involuntary or voluntary exercise, either 
one benefited damaged photoreceptors in animal models of retinal degeneration 
through increased expression of brain-derived neurotrophic factor (BDNF) and 
activation of tropomyosin-related kinase B (TrkB) signaling pathway [85, 86].
Electrical neurostimulation has developed rapidly in recent years, covering 
a range of neurological diseases, such as neurostimulation for epilepsy, spinal 
cord stimulation for chronic pain, brain stimulation for Parkinson’s disease, and 
so on [88]. Electrical neurostimulation in vision research has also made a great 
improvement, from transcorneal, subretinal, to whole-eye electrical stimulation. 
Transcorneal electrical stimulation (TES) was performed in SD rats before or after 
exposure to the intense light for 14 days. Both the stimulation before and after light 
exposure slowed the progression of photoreceptor degeneration. Furthermore, 
TES after light exposure exhibited a longer and better protective effect. The neu-
roprotection effects may result from anti-apoptosis (upregulation of Bcl-2 and 
downregulation of Bax) and increased expression of neurotrophic factors (CNTF 
and BDNF) [89]. Subretinal electrical stimulation (SES) in the eye of Royal College 
of Surgeons (RCS) rats, a commonly used model of retinal degeneration, signifi-
cantly preserved amplitudes of b-wave and oscillatory potential, and implicit times 
of a-wave and b-wave, suggesting the preservation of not only photoreceptors, but 
also signal transmission in the retina [90]. Although the whole-eye electrical stimu-
lation did not provide protection for rod structure in P23H rats, b-wave amplitudes 
and rod sensitivity were significantly increased [91].
Although the neuroprotective strategies mentioned above have acquired promis-
ing results in animal models, damaged human retina can be only partially rescued. 
Miller and colleagues have investigated the underlying reasons using many animal 
models. There are three types of cell death including caspase-mediated apoptosis, 
autophagy-mediated cell death, and necrosis which is regulated by receptor-inter-
acting protein kinases (RIPK). In the animal model of retinal detachment, elevated 
expression and phosphorylation of RIPK together with activation of caspases were 
observed. When either RIPK or caspases were inhibited, no obvious rescue effects 
were demonstrated. However, inhibition of both RIPK and caspases resulted in 
significant protective effects. Similar results were found in the animal model of 
retinal degeneration which experienced both photoreceptor and RPE cell death. In 
this animal model, the dominant type of cell death in photoreceptors was apoptosis, 
while necrotic RPE cells were mainly exhibited. Therefore, therapies that block both 
RIPK and caspase pathways may provide more satisfactory neuroprotection [92].
4.2 Current medicine/neuroprotective agents in clinical trials
Neurotech Pharmaceuticals developed an intraocular drug delivery system 
using encapsulated cell technology, called NT-501, to consistently release CNTF 
in the vitreous for more than 2 years [93]. A double-masked, randomized, 
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sham-controlled, phase II study enrolling 51 GA patients who were randomly 
divided into 3 groups, high-dose NT-501 implant, low-dose NT-501 implant, and 
sham control group, demonstrated promising outcomes after a 2-year evalu-
ation [94]. Another phase II study using intraocular implant secreting CNTF 
in GA patients has also been completed. In this multicenter, double-masked, 
randomized, sham-controlled, 1-year, dose-ranging phase II study, VA stabiliza-
tion, defined as loss of less than 15 letters, was observed in the high-dose group 
(96.3%) versus low-dose group (83.3%) and sham surgery (75%). All the patients 
with best corrected VA ≥20/63 in the high-dose group lost less than 15 letters, 
while it was only 55.6% in the combined group of patients treated with low-dose 
implant and sham surgery. Additionally, increase of retinal thickness was consis-
tent with the stabilization of VA [95].
Brimonidine, an α-2 agonist, is usually used to treat glaucoma patients in 
ophthalmology. Since brimonidine has been reported to protect neuroretinal cells 
in murine models, the effects of this drug on dry AMD patients were under evalua-
tion [96]. A randomized, double-masked, sham-controlled, phase II study involved 
119 patients with bilateral GA who were randomly divided into 3 groups including 
200 μg treatment, 400 μg treatment, and sham control group. The efficacy and 
safety of brimonidine on biodegradable implant were evaluated after intravitreal 
transplantation [97]. But the results were not reliable, so another multicenter study 
is currently performed with larger samples (311 eyes receiving either treatment 
of 400 μg brimonidine on biodegradable implant or sham treatment) and longer 
evaluation period (up to 24 months) [98].
A retrospective analysis was performed to analyze the association between 
intake of l-DOPA and incidence of AMD. The results showed that the onset of 
AMD in individuals prescribed with l-DOPA was 8 years later when compared with 
those without the uptake of l-DOPA. The protective effects of l-DOPA might be 
through GPR143 (the only known l-DOPA receptor) pathway [99, 100].
There are few studies about exercise as a clinical intervention in AMD, and 
the published papers are observational research showing the correlation between 
exercise and prevalence of AMD. A study lasting for 15 years demonstrated that 
active lifestyle with physical exercise 3 times per week or more was associated with 
reduced risk to develop wet AMD [101]. In another cohort study, an inverse rela-
tion was observed between vigorous exercise (≥3 times/week) and occurrence of 
intermediate AMD in women, not in men [102]. In addition, low physical exercise 
was related to the formation of drusen larger than 63 μm [103].
Electrical neurostimulation has already been applied to patients using less 
invasive approaches, such as transcorneal or whole-eye electrical stimulation, to 
protect the structure and function of retinal neurons. In a clinical trial conducted 
by Anastassiou and colleagues, 22 patients with dry AMD received transpalpebral 
electrical stimulation twice a day for 5 days. Most of the patients demonstrated the 
improvement in VA and contrast sensitivity at 4 weeks after the treatment; how-
ever, only contrast sensitivity was significantly different when compared with sham 
control group [104]. Similarly, microcurrent stimulation (150 μA for 35 min) once 
a week for 3 months was applied to both dry and wet AMD. Significantly increased 
VA was demonstrated in dry AMD, but not in wet AMD. Moreover, the number of 
patients showing increased VA was twice as those exhibiting deterioration [105].
5. Conclusions
AMD is believed to have stronger relationship with age. With increase of 
aging population worldwide, more individuals are suffering from visual damage, 
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resulting in poor quality of life for the aged people and elevated cost of medical 
care. In AMD, it is not only the degeneration of RPE cells, but also the neural retina 
degeneration, especially photoreceptors, that leads to the visual impairment. 
Therefore, neuroprotection can be one of the therapeutic strategies to slow, halt, or 
even reverse the progression of retina degeneration. Although the neuroprotective 
interventions that are currently investigated in both animal models and patients 
demonstrate promising results, it is of importance to identify the long-term efficacy 
and safety of these interventions. Only after that, the therapeutics will be provided 
to patients to help them maintain vision and further improve the quality of life.
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